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ABSTRACT 
Liver disease, mainly due to hepatitis C virus (HCV) infection, is a leading cause of 
death in HIV positive patients with access to antiretroviral therapy (ART). HCV 
treatment, which can prevent long-term complications of HCV infection, is available. 
Despite this, only a minority of HIV/HCV co-infected patients initiate HCV treatment. 
We aimed to determine key epidemiological features, including HCV treatment uptake, 
of HIV/HCV co-infection in Sweden.  
In 2009, the IL28B genotype was shown to be strongly associated with spontaneous 
and treatment induced clearance of HCV genotype 1. Patients with HCV genotype 2/3 
and HIV co-infection were less studied. We therefore aimed to study the role of IL28B 
genotype in these sub-groups of HCV infected patients.        
 
In paper I and II, 13 HIV/HCV co-infected and 100 HCV mono-infected patients with 
HCV genotype 2/3 were treated with a lower-than-standard dose of pegylated 
interferon and weight-based ribavirin. Early viral kinetics and treatment outcome were 
studied according to IL28B genotype. In HCV mono-infected patients, IL28B genotype 
CC was associated with a steeper first phase decline during HCV treatment. This did 
not translate into higher sustained viral response (SVR) rates, hence the value of pre-
treatment IL28B genotyping can be questioned in patients with HCV genotype2/3. The 
small number of HIV/HCV co-infected patients included prevents firm conclusions 
regarding this group.  
In paper III and IV, data from InfCare HIV, where all known HIV infected persons in 
Sweden (n=5315) are included, were extracted. Factors associated with spontaneous 
clearance of HCV and HCV treatment were studied in uni- and multi-variate analyses. 
Furthermore, using a questionnaire given to HIV/HCV co-infected patients and their 
attending physicians in Stockholm, we investigated reasons for not having initiated 
HCV treatment yet.  
The prevalence of anti-HCV in the total HIV infected Swedish cohort was 14% in 
2010. This corresponds to a 9-11% prevalence of chronic HCV. 21% had 
spontaneously cleared the HCV infection. Spontaneous clearance of HCV was 
associated with IL28B genotype CC and a chronic hepatitis B virus infection. 
Interestingly, three cases of spontaneous clearance of a chronic HCV infection after 
immune reconstitution induced by ART were seen, all with IL28B genotype CC. The 
HCV treatment uptake was 25%, which is in line with European data and possibly also 
with the treatment uptake in HCV mono-infected patients in Sweden. HCV genotype 
2/3, HIV transmission route other than intravenous drug use (IDU) and on-going ART 
were associated with a higher HCV treatment uptake. No significant differences in 
treatment uptake according to gender, ethnicity or university clinic or not were found. 
A major reason for not having initiated HCV treatment was on-going or recent IDU. 
The higher HIV treatment uptake, and rate of undetectable HIV viral load, indicate that 
many patients who had not initiated HCV treatment were adherent to their HIV 
treatment.  
When interferon-free direct acting antivirals (DAA) combinations soon will become 
available, this changes everything. Again. HCV treatment should then expand to 
include more HIV/HCV co-infected patients in order to prevent morbidity and 
mortality from HCV in this population.  
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1 INTRODUCTION 
In my clinical practice at the HIV outpatient department, I met HIV/hepatitis C (HCV) 
co-infected patients with cirrhosis and end stage liver disease (ESLD).  They had been 
diagnosed with both HIV and HCV a long time ago and were doing well regarding HIV 
with on-going antiretroviral therapy (ART). Even though there is HCV treatment 
available, which can prevent cirrhosis and ESLD, these patients had never tried it. 
There were often reasonable explanations for this, but in some cases, they had just 
never got around to it. I also learned that my colleagues had promoted HCV treatment 
and even treated some that other would consider untreatable with the presently 
available HCV treatment.  
International literature stated that about one out of three HIV patients in the West are 
co-infected with HCV. Among these, liver disease is a major cause of death. Despite 
this, only few patients initiate HCV treatment.   
Considering these factors, I then asked myself: how many HIV/HCV co-infected 
patients are there, not just at our department but in Sweden totally? How many of them 
have initiated HCV treatment? Are all HIV/HCV co-infected patients in Sweden given 
an equal access to HCV treatment? What are the reasons for not yet having initiated 
HCV treatment?  I approached the InfCare HIV database, in which data on all known 
HIV positive patients in Sweden are included, with these questions.   
 
When treating an infection, not only the treatment and the infective agent are of 
importance, but also the person who is infected, the host. Several host factors, including 
genes, can influence treatment response. The study on how genes influence the effect or 
toxicity of drugs is called pharmacogenomics. A major breakthrough for 
pharmacogenomics was seen in 2009, when a genome wide association search 
(GWAS) resulted in the detection of gene variants, single nucleotide polymorphisms 
(SNPs), strongly associated with the response to interferon (IFN)-based HCV 
treatment. This interleukin-28B (IL28B) gene polymorphism actually explained some 
of the difference in response to HCV treatment between ethnic groups that had long 
been observed. The IL28B genotype was also shown to be associated with spontaneous 
clearance of HCV infection.  
At the time of commencement of our studies, the association of IL28B genotype with 
sustained viral response (SVR) in patients infected with HCV genotype 1 was 
established. However, patients with HCV genotype 2 and 3 were less well studied, as 
were HIV/HCV co-infected patients. We therefore decided to study the role of IL28B 
gene polymorphism in these subgroups of HCV infected patients.    
  
In this thesis I will introduce you to HCV and HIV infection separately, before 
attempting to point out the peculiarities of HIV/HCV co-infection. Thereafter, I will 
discuss the four papers included in this thesis. Paper I and II will be handled together as 
will paper III and IV, since patients included in these studies are the same. I then hope 
to conclude something, before you can finally read the acknowledgements.  
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2 HEPATITIS C 
 
2.1 BACKGROUND  
Hepatitis C virus (HCV) was discovered in 1989[1]. The clinical picture of post-
transfusion non-A, non-B hepatitis (NANBH), most of which was later shown to be 
HCV-related, had been recognized since the 1970s[2].  
HCV is a blood-borne virus. In the West it is mainly spread by intravenous drug use 
(IDU), by shared contaminated drug use equipment: needles, syringes and other 
paraphernalia [3, 4]. Before the first anti-HCV test was introduced in the early 1990s 
(1992 in Sweden) transmission via blood products was a major route[5]. Iatrogenic 
HCV transmission continues to occur in low-income countries and sporadic nosocomial 
outbreaks are still reported from high-income countries [5]. HCV can also be 
transmitted vertically, from mother to child, but to a low extent (<5%)[6]. There is a 
very low risk of sexual transmission of HCV in heterosexual couples [7, 8]. Despite an 
on-going outbreak of HCV in HIV positive men who have sex with men (MSM), there 
has been no firm evidence of this epidemic in HIV negative MSM[9].   
 
The hepatitis C virus belongs to the Flaviviridae family and the hepacivirus genus. Its 
genome is about 9600 nucleotides, which encodes a single polyprotein cleaved to three 
structural proteins, and seven non-structural proteins. The single stranded RNA is 
surrounded by a nucleocapsid, which is further surrounded by a cell-derived membrane 
envelope[10].  
The HCV RNA polymerase is error prone and the mutation rate very high. HCV has a 
high rate of replication, 1012 particles are produced every day in an infected person[11]. 
The resulting genetic variability contributes to the high ability of HCV to evade the 
immune system. There is no vaccine available.  
There are 7 genotypes of HCV, with a distinct global distribution. Within each 
genotype, there are also several subtypes (represented by letters, i.e. 1a, 1b)[12].  
Furthermore, quasi-species can be found within infected individuals.  
 
Diagnosis of HCV infection is based on the detection of antibodies against HCV (anti-
HCV) or HCV-antigen by an enzyme immunoassay (EIA) test and a polymerase chain 
reaction (PCR) test for detection of HCV RNA. Until recently, serological methods 
alone were not able to differentiate a past from present HCV infection, but the detection 
of HCV core antigen now allows for this distinction. In acute and chronic HCV, the 
HCV antigen and HCV-RNA tests in blood are positive.  
 
 
2.2 EPIDEMIOLOGY 
HCV causes 499 000 deaths globally every year, and is ranked number 25 in global 
causes of deaths [13]. End stage liver disease (ESLD) caused by HCV infection is a 
leading cause of liver transplantation. The mortality due to HCV has increased by 50% 
between 1999-2007 and exceeds that of HIV in the USA at present[14].  
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In Sweden, inpatient care due to serious complications of HCV infection increased in 
the 2000s[15]. 
 
HCV infection affects 180 million persons globally [16]. The earlier estimate from the 
World Health Organisation (WHO) was 130-170 millions, equivalent to a prevalence of 
2.8%. Furthermore, 2.3-4.7 million persons are newly infected every year[17]. The 
HCV prevalence is highest in Central and East Asia, North Africa, and in the Middle 
East [16]. Egypt has an exceptionally high HCV prevalence, 15%, linked to iatrogenic 
spread during schistosomiasis treatment campaigns[18]. In Europe, the prevalence 
varies between 0.13-3.26%, with the highest prevalence found in Italy and Romania 
(The burden of liver disease in Europe, European Association for the Study of the 
Liver, EASL 2013, www.easl.eu). The Nordic countries are low endemic with an 
estimated prevalence of 0.5% [19-21].   
It is estimated that 90% of persons with viral hepatitis (including hepatitis B) in Europe 
are unaware of their disease (The burden of liver disease in Europe, EASL 2013). 
Similarly, in the USA 45-85% are thought to be unaware of their HCV infection [22].  
 
 
 
Figure 1. Estimated global anti-HCV prevalence in 2005.  
From Mohd Hanafiah K, Hepatology 2013, with permission.  
Global&epidemiology&of&hepa00s&C&virus&infec0on:&New&es0mates&of&age<speciﬁc&an0body&to&HCV&
seroprevalence&
Hepatology!
Volume!57,!Issue!4,!pages!133331342,!4!FEB!2013!DOI:!10.1002/hep.26141!
h@p://onlinelibrary.wiley.com/doi/10.1002/hep.26141/full#ﬁg3!
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In Sweden, HCV is a notifiable disease by the Communicable Diseases Act and is 
reported by both the diagnosing clinician and the virology laboratory. Every year 2000 
new cases of HCV are notified in Sweden. Some 55 000 persons have so far been 
notified with HCV since 1990 and it is estimated that about 40 000 are currently living 
with HCV infection (Swedish Institute for Communicable Disease Control, SMI, 
www.smittskyddsinstitutet.se). The notifications, however, are mainly based on anti-
HCV testing alone which means that some of these persons will have cleared their 
HCV infection spontaneously or as a result of HCV treatment, leading to a 
overestimation of the prevalence of chronic HCV.  
 
The majority (65%) of persons notified with HCV have been infected via IDU, and the 
majority of people who inject drugs (PWID) acquire HCV in the first few years after 
starting injecting[23, 24]. In Stockholm, an anti-HCV prevalence of 86.5% was found 
after a median injecting duration of 12 years in PWID 2005. Almost 50% was anti-
HCV positive within 2 years after first injecting drugs[24].  In the recently started 
needle exchange program in Stockholm, the anti-HCV prevalence in 2013 is 74% 
(Martin Kåberg, personal communication).  
The peak prevalence in Sweden occurs in persons born 1950-1960. Many of these 
persons acquired the infection in the late 60ies of 70ies when intravenous drug use 
became more common in Sweden. There is still on-going transmission in PWID, as 
indicated by a stable HCV incidence in persons in their 20ies.  
Blood transfusion was the probable route of transmission in 6% of persons notified 
with HCV in Sweden. In 26% the transmission route was unknown, however many of 
these cases may be IDU-related[15, 23].  
 
 
2.3 NATURAL HISTORY  
An acute HCV infection is spontaneously cleared in 15-50%[25, 26]. Hence, the 
majority of infected patients develop chronic HCV, defined by a disease duration of 
more than 6 months. Once the infection has become chronic, spontaneous clearance of 
HCV is extremely rare[27].  
Host factors associated with a higher spontaneous clearance rate include female sex, 
age less than 40 years, chronic hepatitis B, a favourable IL28B genotype, which affects 
clearance of HCV genotype 1 and 4, certain human leucocyte antigen (HLA) 
genotypes, and a strong persistent CD4+ T-cell response[26, 28-33]. Symptomatic 
patients generally have a higher clearance rate[26].  
Host factors associated with a lower clearance rate include HIV infection[34].  
Viral factors, such as HCV genotype and HCV RNA viral load may also be of 
importance[26, 31].   
 
HCV infects hepatocytes, where it replicates, and is also found in peripheral blood. The 
possibility to infect lymphocytes, monocytes, dendritic cells and also intestinal 
epithelial cells has been suggested[35]. HCV has also been detected in brain tissue[36]. 
The entry of HCV into hepatocytes requires an interaction with multiple host proteins, 
including glycosaminoglycans (GAGs) and low density lipoprotein-receptor (LDL-
R)[35]. The process is incompletely understood.   
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Patients with chronic HCV experience chronic inflammation in the liver and a 
progression of fibrosis, resulting in cirrhosis in 10-30% after 20-30 years[25]. The 
fibrogenesis is not linear and seems to be accelerated when more advanced stages of 
fibrosis are reached[37].  
The risk of fibrosis progression is influenced by many factors, including gender, age, 
alcohol consumption and co-infection with HIV, HBV or schistosomiasis[25].  There is 
no firm evidence that the HCV genotype or viral load affects fibrosis progression, 
however, genotype 3 is associated with more pronounced steathosis[25, 38]. The role of 
the IL28B genotype in fibrosis progression is unclear[39].  
 
Once cirrhosis is present, patients run a 1-4% per year risk of developing hepatocellular 
cancer (HCC). He/she is also at a 3-8 % yearly risk of developing decompensated 
cirrhosis: ascites, variceal bleeding, hepatic encephalopathy or severe bacterial 
infections including spontaneous bacterial peritonitis (SBP)[40-42]. These conditions 
are referred to as end stage liver disease, ESLD.  
Liver transplantation is an established treatment for decompensated liver disease due to 
HCV, and also for small HCCs. However, the HCV invariably relapses in the 
transplanted liver and causes accelerated fibrosis progression in the graft[43].  
 
Only 10-20% of patients with acute HCV experience symptoms (i.e. jaundice, fatigue, 
general flu-like symptoms) and therefore the diagnosis is seldom made in the acute 
stage[26]. The majority of patients with chronic HCV are also asymptomatic. Hence, 
the HCV infection can be undiagnosed for decades. A few patients experience extra-
hepatic manifestations, such as glomerulonephritis, porphyria cutanea tarda or 
cryoglobulinemia-associated vasculitis, which may lead to diagnosis of HCV[42].  
There is also an association between HCV infection and non-Hodgkin lymphoma and 
myeloma [44].   
 
 
2.4 HCV TREATMENT  
With antiviral treatment, HCV infection can be cured in a majority of cases.  
Achieving sustained viral response (SVR), which is regarded as the equivalent of a 
cure, is associated with halted progression and even regression of fibrosis, and a lower 
risk of liver related morbidity and mortality[45, 46].  
 
The first available HCV treatment was interferon (IFN)-alfa (a naturally occurring 
protein, administered by subcutaneous injection), which became available in 1986, 
resulting in SVR rates of 10-30%[47]. The oral nucleoside analogue ribavirin (RBV) 
was added in 1998, improving rates of SVR to 40%[48, 49]. Interferon was modified 
with pegylation (peg-IFN) in 2001; again increasing cure rates and allowing 
subcutaneous injection once weekly instead of three times per week. The SVR rates 
with peg-IFN + RBV is 50% in HCV genotype 1, 80% in genotype 2/3 and 60% in 
genotype 4 [50, 51]. The influence of the IL28B genotype is strong particularly in 
patients with HCV genotype 1. Patients with the favourable genotype CC achieve SVR 
in 80% whereas only 38% of those with CT/TT genotype do so [52].   
 
  6 
The mechanism of action of peg-IFN is thought to be both direct antiviral and immune 
modulating[53]. The mode of action of RBV is not clear, it may be immune modulating 
but its capability of inducing mutagenesis might also be important[54, 55]. RBV seems 
to be of extra importance in the prevention of relapse.  
 
The recommended doses of peg-IFN + RBV varies according to HCV genotype and 
underlying host factors. The treatment duration, 16-24-48 weeks, is response-guided. 
For definitions of virological response, see Table 1.  
In general, the highest peg-IFN dose as well as weight based RBV dosing during 48 
weeks (shortened to 24 weeks if RVR is achieved) is recommended for patients with 
HCV genotype 1 or 4. In patients with genotype 2 or 3, a lower flat dose of RBV can be 
used, and peg-IFN can be given in lower doses with a duration of 24 weeks. Even 
shorter treatment, 12-16 weeks, can be given in genotype 2 and 3 if RVR is achieved 
according to current HCV treatment guidelines [56, 57].  
 
Factors affecting treatment response include:  
Host factors: gender, age, cirrhosis, insulin resistance, steathosis, BMI, ethnicity, IL28B 
genotype, IP 10   
Viral factors: HCV genotype, baseline HCV-RNA viral load 
On treatment response: RVR, EVR 
Out of these, IL28B, RVR and HCV genotype are the strongest predictive factors for 
SVR[32, 52].  
 
Viral kinetics during treatment is a strong predictor of SVR. After the initiation of peg-
IFN+RBV treatment, the HCV RNA viral decline usually follows two phases. The first 
phase, with a rapid decline in the first two days, is thought to reflect the direct antiviral 
effect of the treatment resulting in a block in production or release of new virions. The 
second phase, in which the HCV RNA continues to decline but at a lower pace during 
the following weeks, is thought to reflect the clearing of infected hepatocytes [58].    
 
 
 
Table 1. Definitions of virological response of Peg-IFN+RBV 
 Time HCV RNA 
Rapid virological response (RVR) Week 4 on treatment Undetectable 
Early viral response (EVR) Week 12 on treatment >2 log10 drop from baseline  
Complete EVR (cEVR) Week 12 on treatment Undetectable 
Partial EVR (pEVR)  Week 12 on treatment >2 log10 drop from baseline, 
but not undetectable 
End of treatment response (ETR) End of treatment Undetectable 
Sustained viral response (SVR) 
12/24 
12 or 24 weeks post 
treatment  
Undetectable 
Relapse (RR) End of treatment and 24 
weeks post treatment 
Undetectable at end of 
treatment, detectable 24 weeks 
post treatment 
Non response (NR) 24 weeks post treatment Detectable 
 
  7 
 
While SVR rates of 50-80% of patients are a remarkable achievement, several factors 
limit the applicability of the peg-IFN+RBV treatment. It has numerous side effects, 
making patients and providers hesitant to initiate treatment and sometimes causing 
premature discontinuation of treatment. Also, there are difficult-to-treat patients, 
including those with advanced cirrhosis, who may decompensate and develop ESLD 
during treatment. Renal insufficiency, liver transplant and HIV/HCV co-infected 
patients are also more difficult-to-treat and have lower SVR rates.   
 
In 2011, the first direct acting antivirals (DAAs) became available. In triple therapy, a 
protease inhibitor: telaprevir or boceprevir, active against HCV genotype 1 only, is 
given in combination with peg-IFN +RBV for 12-24 weeks, followed by peg-
IFN+RBV for another 12-24 weeks[59, 60]. This increased the SVR rate by some 20% 
and enabled shortened duration in a large segment of patients, however, also markedly 
increased side effects and cost. This triple therapy is now the current standard of care 
(SOC) treatment in patients with HCV genotype 1 [56].   
In 2014, new DAAs are expected to reach the market, including the nucleoside 
analogue sofosbuvir and the protease inhibitor simeprevir[61]. Sofosbuvir has achieved 
exceptionally high SVR rates with shorter treatment durations and much less side 
effects than the current SOC. Sofosbuvir has a pangenotypic activity and a high barrier 
to resistance[62, 63]. The development of DAAs is a rapidly evolving field, and all-oral 
interferon free treatments are expected to cure most HCV infections within the near 
future [64].  
 
When HCV treatment is given in the stage of acute infection, the SVR rates are higher 
than when treatment is given in the chronic stage, even with peg-IFN mono-
therapy[26]. However, since the majority of HCV infections are asymptomatic and 
hence undiagnosed, treatment in the acute stage is seldom possible. HCV treatment in 
this section refers to the treatment of chronic HCV.  
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HCV treatment uptake 
 
When evaluating the HCV treatment uptake, the purpose of HCV treatment must be 
considered. The main treatment goal today is to prevent HCV related ESLD and death. 
Given the slowly progressive nature of chronic HCV in many patients, not all will have 
an indication for HCV treatment. On the other hand, HCV treatment may be seen as 
prevention and a step towards reducing the HCV incidence and prevalence. Indeed, 
mathematic modelling has suggested the cost-effectiveness of a more widely used 
treatment among PWIDs with a potential to influence the HCV epidemic [65, 66]. The 
“ideal” treatment uptake is thus not defined.  
In addition, reliable HCV treatment uptakes estimates are scarce, since many studies 
may be subject to selection bias[67].   
 
A HCV treatment uptake of 37.5% was reported in 2006 among 10 400 HCV mono-
infected patients based on claims data in the USA [68]. This large study only included 
patients with health insurance, which might lead to an overestimation of the treatment 
uptake.  In a huge (n=99 000) veterans administration cohort in 2005, 12% started HCV 
treatment [69]. However, the results of veterans are not automatically generalizable to 
other populations. A 24% HCV treatment rate was reported in a community-based 
study in Australia [70]. This study was based on self-reported HCV. In a recent meta-
analysis of HCV treatment experience outside of clinical trials, a 19% HCV treatment 
uptake was reported [67].    
 
In an estimation of ever treated prevalent HCV mono-infected patients in 21 European 
countries from 2005, the numbers ranged from 16% in France to less than 1% in 
Russia, Greece, Poland and Romania. The average cumulative treatment rate was 3.5%. 
In Sweden a 12% treatment uptake was reported. This estimate was based on sales of 
peg-IFN and an estimated national HCV prevalence of 0.5%[71].  
In line with this a 14% HCV treatment uptake was reported in Sweden in 2006, based 
on 1000 peg-IFN prescriptions per year between 2001 and 2006 and an estimated 43 
000 HCV infected individuals based on notification data[15].   
More recently, Razavi et al estimated HCV treatment rates 2010 in Europe, again based 
on peg-IFN units sold and estimated national prevalence figures. France had the highest 
HCV treatment rate, 7% followed by Sweden, 4.3%. Italy and Russia had the lowest 
rates: 0.6% and 0.5% respectively (Razavi, abstr 50, International Liver Congress 
2013). 
   
The cost of the current HCV treatment is high, and the price of the coming DAAs will 
probably be even higher. This limits the global access to HCV treatment. Medicins 
Sans Frontiers (MSF) has launched a call for a scale up of HCV treatment, possibly by 
the use of biosimilars.    
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2.5 THE ROLE OF IL28B GENE POLYMORPHISM  
In 2009, a genome wide association search (GWAS) revealed a strong correlation 
between a single nucleotide polymorphism (SNP) at chromosome 19 near the IL28B 
gene and SVR after peg-IFN+RBV treatment in patients with HCV genotype 1 [32, 52, 
72]. The same favourable IL28B genotype was also associated with spontaneous 
clearance of HCV, at least in HCV genotype 1 infections [73]. These associations were 
also found in HIV/HCV co-infected patients with HCV genotype 1 [32, 74, 75]  
IL28B gene polymorphism influences the very early viral kinetics of HCV during peg-
IFN+RBV treatment. This was shown in HCV genotype 1 but not in genotype 2/3 at 
the time of commencement of our studies (paper II).    
The importance of the IL28B genotype in predicting SVR was less clear in HCV 
genotype 2/3 and studies have reported conflicting results[76-79]. Hence, the value of 
pre-treatment testing of IL28B genotype has been debated in patients with HCV 
genotype 2/3.  
 
The distribution of SNPs varies geographically, and explains some of the difference in 
SVR rates noted earlier between ethnic groups[52].  
In 2012, 21 different SNPs near or in the IL28B gene had been analysed. Their impact 
may be different in different populations. So far, the rs 12979860 SNP is the one most 
commonly studied and most extensive evaluated in Caucasians [80].  
 
The mechanism, through which the IL28B genotype and SVR and spontaneous 
clearance respectively are associated, is not well understood. The IL28B gene encodes 
for interferon lambda 3, which induces antiviral activity by itself. It also uses the Janus 
kinas-signal transducer and activator of transcription (JAK-STAT) pathway and 
induces interferon-stimulating genes (ISGs), which also have antiviral activity. 
Favourable IL28B genotypes are associated with lower levels of pre-activated ISGs, 
but are induced more strongly after IFN-alfa treatment [80].  
 
When more effective DAAs are used, host factors are likely to become less relevant. 
The IL28B genotype, however, has a predictive influence on the SVR rates of triple 
therapy including telaprevir or boceprevir[81]. Whether this applies to both IFN-naïve 
and experienced patients is unclear [82, 83]. The role of IL28B genotype in future 
interferon-free HCV treatments remains to be seen, but it is likely to be of much less 
importance.   
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3 HIV 
 
3.1 BACKGROUND 
 
In 1981, a cluster of unusual pneumonias caused by pneumocystis jiroveci (previously 
carinii) was noted in MSM in Los Angeles, San Francisco and New York[84, 85]. It 
soon became clear that a virus caused the immunodeficiency allowing this 
opportunistic infection (OI) in young MSM as well as in haemophiliacs, PWID and 
Haitian immigrants in the USA. The virus was isolated in 1983 by the 
Montagnier/Barré-Sinoussi group and confirmed by Robert Gallo [86, 87]. It was 
initially called lymphadenopathy associated virus (LAV)/Human T lymphocyte virus 
III (HTLV3) and later renamed human immunodeficiency virus (HIV). HIV is the 
causative agent of acquired immune deficiency syndrome (AIDS). HIV is transmitted 
parenterally, sexually and from mother to child.  
 
HIV is a retrovirus, belonging to the lentiviridae genus. It encodes 3 retrovirus typical 
proteins; gag (group-specific antigen), pol (polymerase) and env (envelope) as well as 
16 accessory proteins with regulatory functions. HIV is an enveloped, single-stranded 
RNA virus with a DNA intermediate: a provirus that integrates and persists within the 
host cell DNA.  
The reverse transcriptase, an enzyme central to the HIV replication process, is mutagen 
prone. The virus has a high replication rate of approximately 1010 virus particles per 
day in an infected person. Also, HIV has a high rate of recombination events. Hence, 
the viral evolution is very rapid. The resulting genetic variation contributes to 
immunological escape and confers the risk of resistance to antiretroviral drugs[88].   
 
There are two species of HIV, HIV-1 and HIV-2, where HIV-1 is the virus most spread 
and what is usually referred to when discussing HIV[89].  
HIV-1 is classified into four groups: major (M), novel (N), outlier (O) and P, where M 
is the group dominating the epidemic. There are 9 subtypes, or clades (A, B, C, D, F, G, 
H, J, K) and numerous circulating recombinant forms (CRFs) of the M group[90].  
HIV-1 is believed to have crossed the species barrier from chimpanzee to humans 
around the year 1900 in Africa[91].  
 
Diagnosis of HIV infection is based on serological methods, detecting HIV antigen and 
or anti-HIV antibodies in either blood or plasma by enzyme-linked immunosorbent 
assay (ELISA).  Serological methods can also be applied on saliva.  
HIV-RNA is detected with a PCR method in blood or peripheral blood mononuclear 
cells (PBMCs) from HIV-infected persons. The limit of detection varies between 
assays, but is usually 50 or 20 copies/mL. By ultrasensitive RT-PCR assays, a 
persistent residual low-level viraemia (1-5 copies/mL) can be detected also in patients 
on antiretroviral therapy (ART) with undetectable HIV-RNA by conventional methods.  
This residual viraemia may either arise from latently infected cellular reservoirs or 
represent on-going viral replication.  
 
  11 
 
3.2 EPIDEMIOLOGY 
AIDS is a leading global cause of death, ranking number five as a cause of disability 
adjusted life years (DALY) loss in 2010 Global Burden of Disease [92]. 1.6 (1.4-1.9) 
million people died because of AIDS in 2012 (UNAIDS Global Report 2013, 
www.unaids.org).  Since the beginning of the HIV epidemic, more than 25 million lives 
have been claimed by the disease (HIV/AIDS Fact sheet no 360, WHO, www.who.int).   
In countries with high access to antiretroviral therapy (ART), AIDS is no longer a 
major cause of death. However, late HIV diagnosis, when there is already advanced 
disease with immunosuppression, may still result in death from AIDS in the West. 
About 50% of HIV patients in Europe are “late presenters”, diagnosed when their 
CD4+ T-cell count is below 350 or presenting with an AIDS defining event[93]. It is 
believed that 18% of HIV positive patients in the USA are unaware of their infection 
(Centers for Disease Control and Prevention, CDC, www.cdc.gov).  
 
In 2012, an estimated 35 (32-39) million people were HIV infected worldwide. 
Furthermore, 2.3 (1.9-2.7) million new infections occur every year, which represents a 
33% decline compared to the number of new infections in 2001. (UNAIDS Global 
Report 2013, www.unaids.org)  
The HIV prevalence is highest (up to 25% in persons aged 15-49 years in some 
countries in Southern Africa) in Sub Saharan Africa and in Asia, where the 
heterosexual transmission route dominates. SSA alone is home to 69% of all HIV 
infected persons. The incidence is rising in Eastern Europe and Central Asia, especially 
in PWID. In Europe, 2.3 (2.0-2.7) million people are estimated to be HIV infected, and 
the prevalence in persons aged 15-49 years is 0.4% (WHO, www.who.int).  
 
 
Figure 2. Adults and children estimated to be living with HIV in 2011.  
WHO (www.who.int) 
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HIV is a notifiable disease in Sweden. Between 1983 and 2012, 10 332 persons have 
been notified with HIV. Of these, about 6200 are currently alive. The prevalence in 
Sweden (9600 000 inhabitants) is thus estimated to be 0.06%. The incidence is 
regarded as stable with about 400-500 new cases reported every year. About half of 
these were infected before the arrival in Sweden. The MSM group dominates among 
persons infected in Sweden. In 2007, there was an HIV outbreak in PWID in 
Stockholm. Since then, however, the reported number of cases in PWID has been low 
(SMI, www.smittskyddsinstitutet.se). 
 
 
3.3 NATURAL HISTORY 
A few weeks (7-28 days) after encountering the HIV virus, some patients develop 
symptoms of a primary HIV-infection. These symptoms may include fever, sore throat, 
and exanthema and are commonly mistaken for other viral illnesses. During this initial 
phase of the infection, HIV-RNA viral loads are very high which makes this a very 
infectious stage. In fact, recently infected persons may be driving the HIV 
epidemic[94].  
 
HIV enters the CD4+ T-cells by attaching to the CD4 receptor and co-receptors, CCR5 
or CXCR4.  It also infects resting central and translational memory T-cells, thus 
creating a reservoir of integrated viral DNA. Other reservoirs, including 
monocytes/macrophages and naïve T-cells have also been suggested [95]. Within days 
and weeks, there is a pronounced depletion of CD4+ T-cells in the body, mainly in the 
gut associated lymphoid tissue (GALT) but also in peripheral blood. The mechanism 
for HIV killing of CD4+ T- cell is not entirely clear. HIV is also capable of infecting 
other cells such as monocytes/macrophages, dendritic cells, astrocytes in the CNS, and 
stellate cells in the liver[96, 97].  
 
The pathogenesis of HIV is characterized by a progressive loss of CD4+ T-cells while 
HIV-RNA increases from a set point. Initially the patient is asymptomatic but may later 
develop constitutional symptoms, such as weight loss, diarrhoea, fever, and 
lymphadenopathy. When the CD4+ T-cells reach a certain level, the risk of 
opportunistic infections (OIs) gradually increases. The risk of malignancies, especially 
those driven by viruses, is also increased.  
AIDS refers to advanced stages of HIV infection and is defined by any of more than 20 
OIs or related malignancies, for example pneumocystis pneumonia, cerebral 
toxoplasmosis and Kaposis sarcoma. The median time from HIV infection to AIDS is 8 
years (6-10), however there are large inter-individual variations in the progression rate 
(1-20 years) [98]. A few so-called elite controllers are able to maintain HIV-RNA 
below detection limit and have normal CD4+ T-cell counts in the absence of ART[99]. 
Also, long-term nonprogressors maintain stable CD4+ T-cell counts and are 
asymptomatic but are viraemic[100]. Certain HLA alleles have been found to be 
protective against progression[101]. 
 
The immunosuppression caused by HIV can be partially reversed by ART. With ART, 
most HIV infected persons can lead a healthy life with an average life expectancy just 
below that of a general population [102]. However, there is a residual excess morbidity 
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and mortality even in ART treated individuals [103]. This increased mortality, in 
cardiovascular disease, comorbidities and cancer, seems to be associated with 
inflammation. The mechanism is not clear, but on-going immune activation, possibly 
driven by microbial translocation has been proposed[104].    
 
 
3.4 HIV TREATMENT 
ART is a life-saving treatment, which dramatically reduces morbidity and mortality. 
ART can achieve undetectable levels of HIV RNA in blood. When HIV replication is 
suppressed the CD4+ T-cell count gradually increases and is sometimes restored to 
normal levels.  
ART is also effective as prevention. HIV infected patients with on-going ART have a 
dramatically reduced risk of transmitting HIV to their sero-discordant sexual partners 
[105].   
However, a cure is not achieved with ART, since the interruption of ART almost 
invariably leads to the re-emergence of viral replication and progression towards AIDS. 
Rare cases of persons maintaining an undetectable HIV-RNA viral load after coming 
off ART have recently been reported [106](Persaud D, abstr 48LB 20th Conference on 
Retroviruses and Opportunistic Infections, CROI 2013). These persons all initiated 
ART soon after HIV infection.   
Also, ART is not capable of eliminate HIV proviruses integrated in resting memory T-
cells. Presently, reservoir-cell activating drugs, including histone deacetylase (HDAC) 
inhibitors, are being investigated. The hope is that these drugs may be part of a strategy 
to achieve at least a functional cure of HIV[107].   
  
The first ART was zidovudin in 1987, followed by other nucleoside reverse 
transcriptase inhibitors (NRTI) and non-NRTIs (NNRTI). With the advent of protease-
inhibitors (PI) in 1996, Highly Active Antiretroviral Therapy (HAART) was possible. 
With this treatment, mortality dramatically decreased. Today, more than 20 different 
antiretroviral drugs from 4 classes with different modes of action are available. The 
established treatment principle is combination ART, consisting of 3 active drugs to 
decrease the risk of resistance. The ART drugs of use today in the West are generally 
potent, have a low pill burden and relatively few side effects.  
 
In Sweden, 87% of all known HIV infected patients were on ART in 2012, according 
to the InfCare HIV register.  
Globally, there has been a scale-up in HIV treatment access with a goal to reach 15 
million people with ART in 2015 set up by the UN. In 2012, 9.7 million people in low- 
and middle-income countries had access to ART, representing 61% of those eligible 
according to the WHO 2010 guidelines. However, under the WHO guidelines from 
2013, in which ART is recommended at CD4+ T-cell count <500, this represents only 
34% (UNAIDS Global Report 2013, www.unaids.org).  
 
Despite continuing efforts, there is still no vaccine available against HIV.  
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4 HIV/HCV CO-INFECTION 
 
4.1 EPIDEMIOLOGY 
 
Liver diseases, mainly attributable to HCV, have become a leading cause of death in 
HIV infected persons with access to ART. In several cohort studies liver diseases rank 
among the top three causes of death[108-115].  
ESLD in the HIV/HCV co-infected population has increased over the last 15 years in 
the USA, and is presently an important clinical problem [14].  
However, Weber et al reported a decreasing proportion of deaths attributed to liver 
diseases in the D:A:D cohort 1999-2011 (Weber, abstr THAB0304 AIDS 2012). The 
relative importance of liver diseases as a cause of death must be analysed in connection 
with the prevalence of HCV and hepatitis B in the cohort under study.  
 
Due to shared routes of transmission, especially the blood-borne route, HIV/HCV co-
infection is common with an estimated total anti-HCV prevalence in HIV infected 
persons of 15-30 % in the West [116, 117]. Compared with HIV, HCV is more rarely 
sexually or vertically transmitted.  
The prevalence of HIV/HCV co-infection is depending upon distribution of HIV 
transmission routes and varies in different countries and epidemiological settings. 
PWID generally have the highest HCV prevalence, 72-95%, haemophiliacs 
intermediate, heterosexuals (9-27%) and MSM (1-12%) the lowest [116].  The highest 
co-infection rates are thus reported from countries and settings with a high prevalence 
of blood-borne HIV infection. Up to 70% of HIV infected patients from Eastern Europe 
(Ukraine, Belarus) and 85% among Chinese plasma donors are anti-HCV positive[118, 
119]. In Sub Saharan Africa and Thailand, where the heterosexual HIV transmission 
route dominates, the HIV/HCV co-infection rate is much lower, below 5-10% [120-
122]. Reliable data on HIV/HCV co-infection prevalence are missing from many parts 
of the world. Also, the prevalence may vary within countries, i.e. from 3.7% in rural 
areas to 18% in urban Tanzania[123, 124].  
 
An anti-HCV prevalence of 33% (1960/5957 patients) was reported from the large 
EuroSIDA cohort, which includes patients from about 100 centres in Europe, Israel and 
Argentina in 2005. There were marked regional differences within Europe, with the 
highest prevalence in the East (47%) and South (41%) and a lower prevalence in the 
West (23%) and North (20%) of Europe[119]. In 2008, an anti-HCV prevalence of 
24% (3375/14310 patients), whereof 77% had a chronic HCV infection was reported 
from the same cohort[125]. In a recent publication, the anti HCV prevalence in 
EuroSIDA was reported to be 31% (4044/13025) with 74% being HCV RNA positive 
[126]. 
The prevalence of HIV/HCV co-infection in Sweden has not been studied in detail. In 
the EuroSIDA study from 2005, the reported prevalence in Sweden was 29% based on 
a sample of 205 Stockholm patients of known HCV serostatus [119]. When sampling 
only from Stockholm, the IDU transmission route might be overrepresented and hence, 
the co-infection prevalence overestimated.   
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Since 2004, there is an on-going HCV epidemic in HIV-positive MSM in Europe, the 
USA and Australia. In this group the prevalence and incidence is increasing but from a 
low level. Acute HCV infection in this setting has been associated with mucosal 
damage, non-injected drugs and other sexually transmitted infections (STI). The HCV 
genotypes seen are commonly genotype 1 and 4, and large transmission networks 
related to permucosal injury have been identified using phylogenetic analysis[127, 
128].  
   
 
4.2 NATURAL HISTORY 
 
4.2.1 The effect of HIV on HCV infection 
HIV alters the natural history of HCV, accelerates the rate of fibrosis progression and 
aggravates the complications of HCV.   
 
HIV infected persons have an increased rate of sexually transmitted HCV infection. 
This is the case for HIV-infected MSM (see above), but also the heterosexual 
transmission rate might be increased even though evidence is weak [117, 129, 130]. In 
addition, an increased rate of mother to child transmission of HCV has been reported in 
HIV infected persons [6, 131].  
 
A lower rate of spontaneous clearance of an acute HCV infection is generally seen in 
patients with HIV infection [34]. The association of IL28B genotype with spontaneous 
clearance of HCV has been reported also in HIV/HCV co-infected patients [32]. 
However, at the time of initiation of our studies, this was less well established than in 
mono-infected patients.  
  
Clearance of chronic HCV infection without specific HCV treatment is rarely seen, but 
several case-reports in HIV/HCV co-infected patients have previously been 
published[132-138]. Most of these cases, if not all, have been associated with immune 
reconstitution after initiation of ART. 
Interestingly, there are also a few case reports of spontaneous clearance of chronic 
HCV in the post-transplant setting in HCV mono-infected persons[139, 140].  
 
HIV/HCV co-infected patients tend to have a higher HCV-RNA set point, on average 
one log higher than mono-infected patients [141, 142]. The effect of ART on the viral 
load is somewhat unclear. Several studies report a lower HCV RNA viral load after 
successful ART, sometimes following a short increase in HCV RNA after initiation of 
ART [141, 143]. In a recent study, ART was associated with stable HCV RNA levels 
whereas HCV RNA increased in the absence of ART[144].  
 
Fibrosis progresses more rapidly in HIV/HCV co-infected than HCV mono-infected 
patients [145-150]. This is evident even with moderately lowered CD4+ T-cell counts 
[151]. The mechanism remains unclear. HIV related immunosuppression, ART related 
liver toxicities, a direct effect of HIV on hepatic stellate cells or amplified microbial 
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translocation has been proposed.[96, 117, 141]. The faster rate of fibrosis progression is 
partially, but probably not fully, reversed by ART although the data are conflicting [37, 
152-154].  ART should therefore be started early in co-infected patients 
[155](European AIDS Clinical Society, EACS, guidelines 2013 v7.0, 
www.eacsociety.org). Also in patients with decompensated liver cirrhosis, there is a 
clear survival benefit of ART [156].  
 
Liver cancer has been increasingly reported in HIV/HCV co-infected patients [14, 110, 
157-161]. A shorter time from HCV infection to HCC and a higher prevalence of 
metastatic disease at the time of diagnosis has been suggested in HIV/HCV co- versus 
HCV mono-infected patients [162-164]. However, other studies did not find an 
increased risk of HCC in co-infected patents, and the effect of HIV on development of 
HCC is not clear [165]. International guidelines recommend that HIV/HCV co-infected 
patients with established liver cirrhosis are included in HCC-surveillance programs 
(EACS, guidelines 2013 v7.0, www.eacsociety.org).   
 
If liver decompensation occurs, the prognosis of HIV/HCV co-infected patients is very 
poor, and hence, these patients need to be evaluated at a liver transplant unit [166]. The 
reported post transplantation 5 years survival is 55%, which is lower than in HCV 
mono-infected patients, 71-75% [167, 168]. There is no accelerated progression of HIV 
in the post-transplant setting. Drug interactions can be problematic but are usually 
manageable. However, there is invariably a HCV recurrence, which is associated with 
accelerated liver fibrosis and a risk of fibrosing cholestatic hepatitis[169].   
  
 
4.2.2 The effect of HCV on HIV infection 
This is an area of uncertainty. The current understanding is that HCV infection does not 
have any major effect on HIV disease progression or the effect of ART.  
 
An increased all cause mortality in HIV/HCV co-infected patients versus HIV mono-
infected has been reported [170, 171]. This increased mortality, however, seems to be 
driven by excess liver related and IDU related deaths and not by HIV disease 
progression[126, 172-174]. A nationwide cohort study from Denmark reported a higher 
mortality in HIV/HCV co- versus HCV mono-infected patients, but this was 
exclusively driven by HIV-related immunosuppression[175].       
Some studies report a lower rate of CD4+ T-cell increase after the initiation of ART in 
co-infected patients [170, 176]. One possible explanation would be that cirrhosis per se 
is associated with lower CD4+ T-cell counts [177]. Adherence to ART may also be 
lower in co-infected patients due to IDU[178]. 
The risk of chronic kidney disease was also increased in HIV/HCV co-infected versus 
HIV mono-infected patients and associated with HCV RNA viraemia[179, 180].    
 
HIV/HCV co-infected patients have an increased risk of hepatotoxicity following ART 
initiation. For this reason certain antiretrovirals, such as nevirapine, tipranavir, 
didanosine and stavudine, should be avoided in co-infected patients. Hepatotoxicity, 
however, is reported with other ART drugs as well. The advantages of ART outweighs 
the risk of hepatotoxicity, which is usually manageable [155].  
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4.3 HCV TREATMENT IN HIV/HCV CO-INFECTED PATIENTS 
 
4.3.1 General principles  
The main principles of, indications and contra-indications for HCV treatment are the 
same in HIV/HCV co-infected as in HCV mono-infected patients.  Given the faster 
progression of fibrosis in HIV/HCV co-infected patients the treatment indication is 
sometimes considered stronger than in HCV mono-infected. Accord to this view, HCV 
treatment should be considered regardless of fibrosis stage[181]. Current guidelines 
though recommend HCV treatment in co-infected patients with fibrosis stage 2 or 
higher [56] (EACS guidelines 2013 v7.0, www.eacsociety.org). At present, the 
development of new DAAs must be taken in account, and many patients might benefit 
best from awaiting these.  
On-going opportunistic infection/AIDS is an added contra-indication.  
 
The predictors of SVR to peg-IFN and RBV are the same as in HCV mono-infected 
patients, including IL28B gene polymorphism in patients with HCV genotype 1 [80, 
182]. Recently, an association of human leucocyte antigen E (HLA-E) polymorphism 
with SVR was reported in HIV/HCV co-infected patients [183].  
Patients with lower baseline CD4+ T-cell count or percentages tend to have a lower 
SVR rate. If HIV-RNA is suppressed and CD4+ T-cells still remain low, HCV 
treatment can still be initiated. The CD4+ T-cell absolute count decreases substantially 
during IFN treatment due to IFN induced neutropenia, but the percentage of CD4+ T-
cells increases slightly. There are limited data on the risk of opportunistic infections in 
this setting, but it is probably low [184, 185]. 
 
HIV/HCV co-infected patients have lower rates of SVR after peg-IFN+RBV treatment 
compared with HCV mono-infected. Approximately 30 (17-36%) in HCV genotype 1 
and 70 (44-82)% in HCV genotype 2/3 co-infected patients achieve SVR[186-193]. 
The reason for this is not fully understood. Inadequate RBV doses, frequent dose-
reductions, treatment discontinuations, drug-drug interactions (DDIs) with ART, higher 
baseline HCV RNA viral load, higher proportion of cirrhosis and other co-morbidities 
have been suggested.  As peg-IFN is dependent of the patient’s immune response, the 
impairment of cellular responses associated with HIV may also be a factor.  
It is not clear if DAA treatment also will result in lower SVR rates in co-infected 
patients. In the phase 2 studies of telaprevir and boceprevir higher SVR rates, which 
were comparable to historical controls of HCV mono-infected patients, were 
achieved[194, 195]. However, the number of patients included has so far been very 
small.   
Sustained viral response (SVR) after HCV treatment is associated with a lower 
incidence of ESLD and death also in co-infected patients [196, 197].  
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In principle, the same peg-IFN, RBV doses and treatment durations as in HCV mono-
infected patients are recommended[56] (EACS guidelines 2013 v7.0, 
www.eacsociety.org) However, weight-based RBV is recommended in all HCV 
genotypes, even though a large study failed to confirm the importance of this [188]. 
The higher peg-IFN dose is recommended. The use of response-guided therapy of less 
than 24 weeks has not been evaluated in co-infected patients and hence should not be 
used. Patients with genotype 2/3 can be treated for 24 weeks if they achieve RVR.  
For treatment of acute HCV infection, RBV is recommended in combination with peg-
IFN in HIV-infected patients. The use of protease-inhibitors for treatment of an acute 
HCV genotype 1 infection is not established.  
The same dose of telaprevir or boceprevir is recommended, but the treatment duration 
cannot be shortened.  
 
Modifications of ART are sometimes necessary to avoid added toxicities and drug-drug 
interactions (DDI). For example, zidovudine or didanosine should not be given in 
combination with ribavirin due to aggravated anaemia and risk of lactacidosis, 
respectively. These nucleoside-analogues are not recommended parts of ART anymore, 
due to their mitochondrial toxicities.  
There has been controversy as to whether abacavir interacts with ribavirin, possibly due 
to competition of intracellular phosphorylation, resulting in lower SVR rates [198, 
199]. However, the use of abacavir seems not to be a problem provided that weight-
based ribavirin is used[200, 201] (EACS, guidelines 2013 v7.0, www.eacsociety.org).  
The arrival of the first DAAs highlighted the importance of DDI with ART. Telaprevir 
and to a certain extent boceprevir are inhibitors and substrates of CYP3A4, and hence 
interactions with both PIs and NNRTIs, which use the same pathway, is common. An 
important lesson from the first DAAs is that DDIs are difficult to predict, therefore DDI 
studies need to be performed.   
For most patients, unless they have accumulated HIV resistance mutations, ART can be 
modified to avoid clinically relevant interactions with the first generation DAAs.  
 
4.3.2 Timing of HCV treatment versus HIV treatment 
Previously, it was recommended that HCV treatment should be given before ART, in 
order to avoid interactions and added toxicities. This was provided that the CD4+ T-cell 
count was high enough not to warrant ART initiation.  
However, in more recent guidelines, the importance of early ART initiation (<500) in 
co-infected patients, in order to prevent progression of fibrosis and to optimize the 
chance of SVR has been highlighted (EACS guidelines 2013 v7.0, 
www.eacsociety.org). The current trend is to initiate ART earlier in all HIV patients, 
regardless of co-infections (WHO guidelines 2013, www.who.int and Department of 
Health and Human Services, HHS, guidelines 2012, www.aidsinfo.nih.gov/guidelines). 
In clinical practice, as only few patients present with very high CD4+ T-cell counts 
when diagnosed with HIV, the option to treat HCV first is seldom available.    
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4.3.3 HCV treatment uptake  
In general, the HCV treatment uptake has been reported to be low in HIV/HCV co-
infected patients, and regarded lower than in mono-infected patients [67, 202-205]. 
Varying HCV treatment uptake, from 2% to 60%, has been reported in HIV/HCV co-
infected patients, partly depending on the denominator used.  
Only 2% of co-infected patients started HCV treatment in a prospective study in 
Boston[206]. Similarly, only 3% of co-infected patients at Johns Hopkins HIV clinic 
had initiated HCV treatment [207]. A HCV treatment uptake of 7.6% in the EuroSIDA 
cohort was reported in 2004 [208]. However, this was based on anti-HCV positive 
patients and therefore most likely underestimated the treatment uptake. From the Swiss 
cohort a HCV treatment uptake of 12.5% among HCV RNA positive patients was 
reported [209]. In an overview based on surveys to WHO representatives, patient 
advocates and biomedical industries, HCV treatment uptake in 2004 in 23 European 
countries was estimated to be 10% on average, ranging from 0-23%. The reported 
uptake in Sweden was 10% [210]. These reports all concern the period up until 2004, a 
time when evidence of HCV treatment safety and efficacy was available only in HCV 
mono-infected patients.   
 
More lately, a multicentre cohort from USA reported a 20% HCV treatment uptake 
until 2007, with an increasing proportion initiating treatment within the first year [211]. 
Also, a single centre study from Ireland reported a 28% HCV treatment uptake until 
2008 [212]. The higher uptake rates, 30-60%, may have been based on already selected 
patients [213-216]. For example, a 41% treatment uptake was reported from a reference 
HIV/AIDS clinic in Madrid 2008, including only co-infected patients on regular 
follow-up [217].   
 
A cumulative HCV treatment uptake of 25% in 2010 was recently reported in co-
infected patients in the Euro-SIDA cohort [218]. The Euro-SIDA cohort is huge, 
however, it may still be subject to selection bias since usually only a few centres in a 
country report to Euro-SIDA. The HCV treatment rates at these centres may not be 
representative of the whole country.   
 
In contrast with previous studies, a similar HCV treatment uptake of 21% (n=246) in 
co-infected versus 22% (n=15 163) in mono-infected patients with incident HCV in 
2006-2009 was reported by Kirbach (abstr 838, International Liver Congress 2013). 
Although large, this study was based on insurance claims data and hence possibly not 
representative of all co- and mono-infected patients in the USA.  
In a recent meta-analysis, the treatment uptake in HIV/HCV co-infected patients 
(n=1522) was reported to be 16% versus 19% in HCV mono-infected patients (n=13 
583)[67]. Thus, even though the treatment uptake in co-infected patients was lower, the 
difference might not be that great.  
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5 AIMS 
The overalls aims were to  
1. Determine epidemiological key features of HIV/HCV co-infection in Sweden 
2. Correlate the IL28B genotype with spontaneous clearance of HCV and early viral 
kinetics during HCV treatment   
 
More specifically, I aimed to  
1. Study the early HCV kinetics and HCV treatment outcome according to IL28B 
genotype in HCV genotype 2/3 mono and co-infected patients (Paper I and II) 
2. Study spontaneous HCV clearance in HIV infected patients according to IL28B gene 
polymorphism and baseline demographic factors  (Paper III) 
3. Describe the epidemiology of HIV/HCV co-infection in Sweden (Paper IV) 
4. Determine the HCV and HIV treatment uptake in co-infected patients in Sweden 
according to HIV transmission route (Paper IV) 
5. Define factors associated with initiation of HCV treatment (Paper IV) 
6. Define barriers to HCV treatment in co-infected patients in Stockholm (Paper IV) 
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6 MATERIALS AND METHODS   
 
6.1 PAPER I AND II 
 
6.1.1 Patients  
In an investigator initiated HCV treatment study 100 HCV mono-infected and 13 
HIV/HCV co-infected naïve patients with HCV genotype 2 and 3 were recruited at the 
hepatitis and HIV outpatient departments at Karolinska University Hospital in 
Huddinge in 2003-2006. Patients with chronic hepatitis B, other concomitant liver 
diseases, on-going substance abuse or severe psychiatric disease were excluded.  
Ten of 13 co-infected patients had had undetectable HIV RNA levels on ART for a 
minimum of 6 months prior to inclusion. Three co-infected patients had not yet initiated 
ART, all with CD4+ T-cell counts above 350. 
Patients were treated with a lower than standard dose of peg-IFN-alfa (135 
micrograms/week) in combination with weight-based RBV (11 mg/kg/day) for 24 
weeks. Experienced nurses monitored patients during treatment.  
 
6.1.2 Estimation of fibrosis  
According to current Swedish consensus guidelines, HCV treatment was allowed in all 
HCV genotype 2/3 patients regardless of fibrosis stage and hence a liver biopsy was not 
regularly performed. At the time of the study, Fibroscan had not yet been introduced at 
the Karolinska University Hospital. However, in order to estimate the fibrosis stage we 
calculated the AST to platelet ratio index (APRI) and Gothenburg University Cirrhosis 
index (GUCI).  
 
6.1.3 Viral outcome definitions  
The standard definitions of viral responses: RVR, cEVR, pEVR, ETR, SVR and NR 
(see Table 1 in the introduction) were used.  Patients who failed to achieve pEVR 
stopped treatment.  
In paper II, the decline in HCV RNA levels was analysed during the 1st phase, from 
baseline to treatment day 2, and 2nd phase, from day 2 to treatment week 2 or 4.  
 
6.1.4 Virological methods 
HCV RNA levels were analysed using the Roche Taqman Real-Time PCR (detection 
limit of 15 IU/ml). HCV genotyping was performed with a line probe 
assay (Inno-LiPA HCV II, Innogenetics NV, Gent,Belgium) or an in-house method 
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6.1.5 IL28B genotyping (Paper II) 
All patients were tested for IL28B rs 12979860 SNP with a Taqman-based allele-
specific PCR method (Applied Biosystems Inc, Foster City, CA,USA), using the ABI 
7500 Fast equipment. For details, see paper II.  
The SNP was defined as rs 12979860 genotype CC, CT or TT genotype.  
We did not assess deviations from the Hardy-Weinberg equilibrium. 
 
6.1.6 Statistics  
In paper I, the 13 HIV/HCV co-infected patients were matched to 2 HCV mono-
infected control patients. Matching for genotype, baseline viral load, and age (+/-5 
years), was done in that order by an investigator blinded to all other baseline 
demographic factors and treatment outcomes. 
In the analysis, the HIV/HCV co-infected patients, their 26 HCV mono-infected 
controls, and the total 100 HCV mono-infected patients were compared. 
Differences between groups were compared with chi-square test or Fisher´s exact two-
tailed for categorical variables. The Wilcoxon Rank Sum test was used for continuous 
variables.  
 
In the univariate analysis of baseline factors associated with RVR or SVR, we included 
disease duration, APRI score, gender, weight, baseline HCV RNA viral load, HCV 
genotype 2 versus 3 and IL28B SNP CC versus non-CC. As no baseline factor was 
significantly associated with SVR (at the <0.10 level), no multivariate analysis was 
performed (paper II). 
A p-value of < 0.05 was considered statistically significant.     
All data were analysed using JMP software version 9.0.0.  
 
6.1.7 Ethics 
Study I and II were performed in accordance with the Helsinki declaration and were 
approved by the Regional Ethics committee (Dnr 250/03, including an amendment, and 
2010/1782-31).  
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6.2 PAPER III+IV  
 
6.2.1 Patients 
6.2.1.1 InfCare HIV database 
More than 99% of all known HIV positive patients in Sweden have been prospectively 
included in the InfCare HIV research database since 2009. Retrospective data from the 
beginning of the 1990-s have also been included from patients in Stockholm and 
Gothenburg.  
On the 28th of September 2010, 5315 adult living persons were known to be HIV 
infected in Sweden. 
Demographical data of all living anti-HCV and anti-HIV positive adults (n=652) (>/= 
18 years) were extracted including age, sex, ethnicity, HIV transmission routes, clinical 
data (prior AIDS diagnosis, CD4+ T-cell count), virological data (anti-HCV serology, 
HCV-RNA levels, HCV genotype, HIV-RNA levels, HBV serology), and HCV and/or 
HIV treatment data (HCV treatment and ART).   
 
6.2.1.2 The Stockholm cohort (Paper IV) 
In Stockholm, two outpatient departments provide specialised health care for HIV 
infected adult patients: the Karolinska and Venhälsan at Södersjukhuset. Together they 
provided care for 2732 (51%) of the 5315 HIV infected patients in Sweden in 2010.  
In total, 322 patients in Stockholm were HIV/HCV co-infected. The Stockholm cohort 
thus constituted 69% of the total HIV/HCV co-infected cohort in Sweden.  
82 (25%) had received HCV treatment whereas 240 had not. These 240 persons were 
considered eligible for inclusion in the questionnaire-based study of barriers to HCV-
treatment.   
As a comparison, 77 HCV mono-infected patients at the Karolinska hepatitis outpatient 
department were included in the same study.   
 
6.2.2 Viral outcome definitions 
Chronic hepatitis C was defined as a positive HCV-RNA test in an anti-HCV positive 
individual. Spontaneous clearance of HCV was defined as a treatment naïve patient 
with a positive anti-HCV test but a negative HCV-RNA test.  
A patient was defined as having a chronic hepatitis B virus (HBV) infection if HBsAg 
was positive, and to have had a previous HBV infection if anti-HBc (+/- anti-HBs) 
were positive with a negative HBsAg test, and to be immune to HBV from vaccination 
when anti-HBs was positive as an isolated test.  
 
Hepatitis C treatment had been given with IFN or peg-IFN alone or in combination 
with RBV. The standard definitions of SVR and NR were used (see Table 1, page 6).  
Persons who had received HCV treatment for an acute hepatitis C (n=5) were excluded 
from the analyses of factors associated with spontaneous clearance and treatment of 
chronic HCV.   
An undetectable HIV RNA viral load was defined as <20 HIV RNA copies/ml. 
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6.2.3 Virological methods  
Analyses of HIV-RNA, anti-HCV antibodies, and HBV serology were performed at the 
local virological laboratories by routine techniques. HCV RNA was analysed in anti-
HCV positive individuals with the Roche TaqMan Test (detection limit of 15 IU/ml). 
HCV genotyping was performed with a line probe assay or an in-house method.  
 
6.2.4 IL28B genotyping  (Paper III) 
Anti-HCV positive patients from the Stockholm area (n=263) were tested for IL28B rs 
12979860 SNP. For details, see paper III.  
 
6.2.5 Questionnaires  (Paper IV) 
A questionnaire was given to HIV/HCV co-infected patients in the Stockholm area who 
had not yet initiated HCV treatment investigating the underlying reasons. The attending 
physician was given a separate questionnaire for every patient he/she cared for whom 
had not yet initiated HCV treatment.  
 
Reasons for not having initiated treatment were categorized as IDU/alcohol (on-going 
or recent abuse), patient desire not to start (including not motivated to initiate HCV 
treatment, fear of side effects, loss of income in case of sick leave and unstable social 
situation), doctors recommendation (including no indication due to mild fibrosis or 
recommendation to postpone treatment until better HCV treatments become available), 
psychiatric disease, comorbidities (somatic contraindication to HCV treatment, 
including ESLD, excluding HIV-related contra-indications), HIV/AIDS (uncontrolled 
HIV infection, on-going opportunistic infection), don´t know or other.  
The questionnaires from every patient-doctor pair were assessed for agreement or 
discrepancies in reasons stated for not having initiated HCV treatment.  
For comparison, HCV mono-infected patients and their attending physician at the 
Karolinska University Hospital hepatitis outpatient department were given the same 
questionnaires.  
 
6.2.6 Statistics  
Differences between groups were compared with chi-square test for categorical 
variables and the Wilcoxon Rank Sum test for continuous variables.  
 
In the univariate analysis of factors associated with spontaneous HCV clearance, we 
included age, sex, ethnicity, HIV transmission route, prior AIDS diagnosis, CD4+ T-
cell cell count, present ART, plasma HIV-RNA level, HBsAg status, and IL28B 
genotype. (Paper III) 
 
In the univariate analysis of factors associated with initiation of HCV treatment we 
included age, sex, ethnicity, born in Sweden or not, HIV transmission route, prior 
AIDS diagnosis, CD4+ T-cell count, present ART, plasma HIV-RNA level, HBsAg 
status, HCV genotype and department (university clinic or not). (Paper IV) 
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Factors with a p-value <0.10 were included in a multivariate model. Logistic regression 
was used to identify variables associated with spontaneous HCV clearance or initiation 
of HCV treatment, respectively.  
The results are presented as odds ratio (OR) and adjusted OR (aOR) with 95% 
confidence intervals (CI).   
A p-value of < 0.05 was considered statistically significant.     
All data were analysed using JMP software version 9.0.0.  
 
6.2.7 Ethics 
The studies were performed in accordance with the Helsinki declaration and were 
approved by the Regional Ethics committee (Dnr 2010/1782-31 and 2011/514-31/1).  
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7 RESULTS AND DISCUSSION  
7.1 PAPER I+II 
 
7.1.1 HCV treatment outcome (Paper I and II) 
The baseline demographics in the 13 HIV/HCV co- and 100 HCV mono-infected 
patients are shown in table 1, paper I.  
The tolerability of HCV treatment was high: only one of the HCV mono-infected 
patients withdrew prematurely from treatment due to an adverse effect. All 13 
HIV/HCV co-infected patients completed treatment. This was probably due to the low 
peg-IFN dose used and support from the treatment staff.  
The HCV treatment outcome, according to RVR or not, is illustrated in Figure 1 paper 
I. In total 77% of co-infected patients, 77% of their matched mono-infected controls 
and 86% of all mono-infected patients achieved SVR. The ability of RVR to predict 
SVR was high.  
 
This small study suggests that patients with well controlled HIV and HCV genotype 2/3 
can be treated with lower-than-standard doses of peg-IFN with satisfactory results. 
However, this would need to be evaluated in a larger randomized trial comparing the 
higher with the lower dose of peg-IFN.  
 
In a single-arm trial, 58 HIV/HCV co-infected patients with HCV genotype 3 were 
treated with a lower-than-standard peg-IFN and RBV (800 mg). A 58% SVR rate was 
reached [219]. In a non-randomized trial in 106 HIV/HCV co-infected patients with 
HCV genotype 3, the lower-than-standard dose was compared with the higher peg-IFN 
dose in combination with RBV (800 mg). The HCV viral decline during the first 4 
weeks was less in the lower dose group, even though this did not result in significantly 
lower RVR rates (73 vs. 60%, p=0.17). SVR rates were not reported[220]. Of note is 
that both these trials used a flat dose of RBV (800 mg), thereby changing two 
parameters at the same time. They also included only HCV genotype 3 patients, which 
generally have lower SVR rates than genotype 2 patients.  
 
The strikingly complicated title of paper I reflects our efforts to interpret the previously 
published viral kinetic part of the study. There was no difference in early viral kinetics 
between HIV/HCV co-infected and their matched HCV mono-infected patients [221]. 
Did the matching process, including the matching on baseline viral load, introduce 
some bias? We added estimates of fibrosis and disease duration and then compared the 
co-infected patients with the total HCV mono-infected group, without finding any 
major differences. The more general question behind the study was whether HIV/HCV 
co-infected patients with well controlled HIV are really that different from HCV mono-
infected patients regarding response to HCV treatment? To answer this question, 
however, a large study comparing HCV treatment outcomes in co- and mono-infected 
patients would need to be designed. Due to the currently changing treatment landscape 
of HCV, this is no longer relevant to do with an interferon-based treatment, but would 
be interesting if a combination of the coming DAAs were used.  
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7.1.2 Prevalence of IL28B genotypes in the study population (Paper II) 
The result of IL28B genotyping was available in all but one HCV mono-infected 
patient. In the HCV mono-infected patients, the overall prevalence of IL28B genotype 
CC, CT and TT was 44%, 52% and 4%, respectively. In the HIV/HCV co-infected 
patients, the corresponding figures were 46%, 46% and 8%. This is similar to a North 
European study of mainly Caucasian patients with HCV genotype 2/3, where the 
corresponding allele frequencies of 44%, 45% and 11% were found [222].  
 
7.1.3 Baseline factors according to IL28B genotype (Paper II) 
Baseline factors according to IL28B genotype are outlined in Table 1, paper II.  
Baseline HCV-RNA viral load was significantly higher in HCV mono-infected patients 
with IL28B genotype CC than CT/TT (non-CC), 9 750 000 versus 2 000 000 IU/mL 
(p=0.02). This is in line with other reports showing higher HCV-RNA levels in HCV 
genotype 1, even though the association is less firmly established in HCV genotype 2/3 
infections [52, 76, 222].    
 
7.1.4 Early viral kinetics according to IL28B genotype (Paper II) 
The early viral kinetics according to IL28B genotype in HCV mono-infected patients is 
shown in Figure 3. Of note is that Figure 3b and 3c actually shows the difference in 
HCV RNA levels between two time points, not the absolute levels. In the HCV mono-
infected patients, IL28B genotype CC was associated with a steeper first phase decline 
during HCV treatment, 2.03 vs. 1.37 log 10 IU/mL, p=0.01 (Figure 3b).   
However, since patients with genotype CC had higher baseline HCV RNA viral loads 
(Figure 3a), the decline started from a higher HCV RNA level but later approached the 
absolute levels of non-CC genotype patients (data not shown). Others have reported 
this association of the IL28B genotype with first phase decline during HCV treatment 
in HCV genotypes 1-4 [79, 223, 224].  
 
The early viral kinetics in the HIV/HCV co-infected patients are depicted in Figure 2, 
paper II. No significant difference in viral kinetics according to IL28B genotype was 
noted in this group, probably because of the small number of patients included.  
 
7.1.5 HCV treatment outcome according to IL28B genotype (paper II) 
The HCV treatment outcome according to IL28B genotype is depicted in Figure 3, 
paper II. Despite the effect on early viral kinetics in the HCV mono-infected patients, 
no significant effect of the IL28B genotype on RVR or SVR was found in either our 
HCV mono- or HIV/HCV co-infected patients. In total, 70% of mono-infected patients 
had RVR, and out of these more than 95% achieved SVR, regardless of IL28B 
genotype.  
 
In univariate analyses, no baseline factor, including IL28B genotype, was significantly 
correlated with SVR and only disease duration with RVR (P = 0.04). Baseline HCV 
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RNA was nearly significantly associated with RVR (P = 0.057). 
Since HCV genotypes 2/3 have higher SVR rates, the sample size needed to show 
significant associations with SVR is larger than in HCV genotype 1.  
 
There have been conflicting reports on the association between IL28B genotype and 
SVR in HCV genotype 2/3 patients. A recent meta-analysis reported a significant 
association between IL28B genotype and SVR in HCV genotype 2/3 but with lower 
strength than in HCV genotype 1 and 4 patients. They therefore agreed with our 
conclusion in paper II, that pre-treatment testing of IL28B genotype was of limited 
usefulness in patients with HCV genotype 2/3 [80].  
 
The coming DAAs, which also are active against HCV genotype 2/3, are expected to 
make IFN-free HCV treatment possible for most of HCV infected patients in the near 
future. With the more potent antiviral activity of the DAAs, the role of host factors 
(including HIV co-infection and IL28B genotype) will probably be less important. 
Perhaps, HIV/HCV co-infected patients might achieve similar response to DAA 
treatment as HCV mono-infected patients. In a telaprevir-based triple therapy study, 33 
HIV/HCV co-infected patients were compared with 116 HCV mono-infected patients. 
SVR12 did not differ significantly between groups but actually tended to be higher in 
co-infected patients, 61% vs. 42%, p=0.06 [225]. However, if this will be repeated in 
larger studies and valid for other DAAs remains to be seen.  
 
Figure 3. HCV RNA levels at a) baseline b) 1st phase decline c) 2nd phase decline during peg-
IFN+RBV treatment according to IL28B genotype CC versus non-CC in HCV genotype 2/3 
mono-infected patients (n=99) 
a b
c 
P < 0.02 P < 0.01 
P = 0.11 
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7.2 PAPER III+IV 
 
7.2.1 HIV positive patients in Sweden (Paper III and IV) 
In total, 5315 persons >/= 18 years were known to be HIV positive in September 2010. 
The transmission route for HIV was heterosexual in 50%, men who have sex with men 
(MSM) in 32%, and IDU in 8%. Transmission via blood transfusion, mother to child 
transmission, and via other or unknown routes accounted for less than 10%. The HIV 
treatment rate was 82% and varied significantly according to HIV transmission route. 
Among persons infected via blood transfusion ART was on-going in 90%, in MSM 85 
%, in heterosexuals 83% and in PWID 75 % (data not shown).  
 
7.2.2 Prevalence of anti-HCV (Paper III and IV) 
In 4765 (90%) persons anti-HCV test results were available whereof 652 (14%) were 
anti-HCV positive (Figure 4). 550 patients (10%) lacked an anti-HCV test result. For a 
comparison of anti-HCV tested versus non-tested patients, see paper III.  
 
The prevalence of anti-HCV varied markedly according to HIV transmission route. 
Hence, 98% of PWID, 41% of persons who acquired HIV via blood transfusion, 5.5% 
of heterosexually HIV infected, and 3.7% of MSM were anti-HCV positive (p<0.01) 
(Figure 2, paper IV). This is in line with other reports [116, 119, 126].  
Among persons who had acquired HIV in Sweden the anti-HCV prevalence was 26% 
versus 6.2% in persons who were infected abroad, p<0.0001. When stratifying for HIV 
transmission route, the differences were still significant in all transmission routes 
except for MSM (data not shown).  
The anti-HCV prevalence was higher in males than in females, 15% versus 12%, 
p=0.01. When analysing only persons with heterosexual HIV transmission route 
though, there was no significant difference in anti-HCV prevalence between males and 
females, 6.4% versus 4.8%, p=0.10 (data not shown).    
 
The 14% prevalence of anti-HCV in the Swedish HIV positive cohort is low by 
international comparison. It is also lower than previously reported from Sweden [119]. 
One possible explanation is the distribution of HIV transmission routes in the total 
Swedish cohort. PWID, who generally have the highest anti-HCV prevalence, only 
make up 8% of the Swedish cohort. Also, the near universal (90%) testing might result 
in a lower total prevalence. Since the 10% not tested were more likely to have a low 
anti-HCV prevalence we might even have overestimated the prevalence somewhat.  On 
the other hand, the on-going HCV epidemic in the MSM group might not have been 
fully captured, since not all clinics had yet implemented yearly anti-HCV testing in this 
group. 
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Figure 4. HIV infected patients with chronic HCV in Sweden 2010 
 
 
7.2.3 Chronic HCV in HIV infected individuals (Paper III and IV) 
HCV RNA testing had been performed in 598/652 (92%) patients of whom 79% tested 
positive (Figure 4). These were defined as having a chronic HCV infection, 
corresponding to a chronic HCV prevalence of 11%. For a comparison of HCV-RNA 
tested versus non-tested patients, see paper III.  
 
Demographics in the 466 HIV/HCV co-infected patients in Sweden are depicted in 
Table 1 (paper IV). Among heterosexuals, 33%, originated from countries with 
moderate (1.5-3.5%) to high (>3.5%) HCV prevalence (data not shown) [16]. 
In total, 79% patients had on-going ART of whom 76% had undetectable HIV RNA 
levels (Table 1, paper IV). The rate of undetectable HIV viral load did not differ 
significantly according to HIV transmission route (data not shown). 
 
HCV genotyping was available in 76% of the HIV/HCV co-infected individuals. HCV 
genotype 1, 2, 3a and 4-6 was seen in 52%, 12 %, 31%, and 6.2% respectively. 
Genotype 1a constituted 75% of all genotype 1 cases. The domination of HCV 
genotype 1 stresses the need for new more effective DAAs to improve SVR rates. The 
genotype distribution is similar to the one reported in HCV mono-infected patients in 
Sweden and in the Euro-SIDA cohort [126, 226]. In Sweden, however, genotype 2 is 
more and genotype 4 less common.  
 
Only eight persons (1.7%) also had a chronic hepatitis B virus infection. 68% had had a 
past HBV infection and 6.0% were isolated anti-HBs positive (data not shown). Hence, 
a previous HBV infection was very common, but only few were registered as HBV 
vaccinated. This probably reflects under registration, but also indicates that the HBV 
vaccination rate can be improved.  
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An alternative way to calculate the prevalence of chronic HCV in the Swedish cohort is 
to exclude patients who had a HCV treatment induced clearance of their HCV 
infection. Out of the 471 initially HCV RNA positive individuals, 61 persons had 
achieved SVR. Hence, there were 410 HIV infected persons with chronic HCV in 
Sweden in September 2010.  This corresponds to a HIV/HCV co-infection prevalence 
of 9% (410/4765=8.6% of anti-HCV tested or 410/(4765-54)=8.7% of HCV-RNA 
tested).  
The HCV genotype distribution in these 410 HIV/HCV co-infected persons is slightly 
different from the one reported above. HCV genotype 1, 2, 3a and 4-6 was seen in 
56%, 9.2%, 28%, and 6.9%, respectively. This is due to enrichment of HCV genotype 1 
as a result of lower SVR rates in patients with this genotype.  
 
7.2.4 Factors associated with spontaneous clearance of HCV (Paper III) 
Spontaneous clearance of HCV was noted in 127/593 (21%) patients. This is within the 
expected range for co-infected persons. Also, many patients might have cleared their 
HCV before they became HIV positive, even though we do not have enough data on 
the consecutive order in which the HIV and HCV infections were acquired. PWID most 
likely acquired HCV before HIV, since the prevalence of HCV is high but HIV is still 
rare among Swedish PWIDs [24]. Furthermore, the risk of HIV transmission of by 
shared drug injection equipment is lower than with HCV transmission [227].  
We were able to document seroconversion for HCV after the HIV diagnosis in 28% of 
the MSM group. Sexually transmitted HCV among HIV positive MSMs is an on-going 
epidemic [228].  
 
In uni- and multi-variate analyses the only factor significantly correlated with 
spontaneous clearance of HCV in our 593 patients was HBsAg positivity. In total, 50% 
of HBsAg positive persons (n=16) cleared HCV vs. 21% in HBsAg negative persons. 
An adjusted odds ratio (aOR) of 17.3 (2.42-125.6), p=0.003 for spontaneous clearance 
of HCV was seen in HBsAg- positive versus -negative persons.  
The association of chronic HBV infection and spontaneous clearance of HCV has been 
previously reported [30, 125, 229, 230]. The mechanism is not clear, but viral 
interference has been proposed [231].  
 
Spontaneous HCV clearance was seen in 26% females and 19% males, p=0.0563, 
which is borderline significant. Female gender has previously been associated with 
higher spontaneous clearance rate of HCV [31, 125, 229].  
 
7.2.5 IL28B genotype and spontaneous HCV clearance (Paper III) 
IL28B genotyping was performed in 263 anti-HCV positive patients followed at the 
Karolinska University Hospital. Their demographics, and IL28B distribution are 
depicted in Table 3, paper III.  For a comparison of IL28B genotype tested versus non-
tested patients, see paper III. Differences in baseline demographics in IL28B genotype 
tested versus untested patients were noted but were unlikely to have had any major 
impact on the overall results. 
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A strong correlation between IL28B genotype and spontaneous HCV clearance was 
noted. Thus, 36% of individuals with CC versus only 13% with non-CC had 
spontaneously cleared their HCV infection, p=0.0003, aOR 5.45 (2.22-14.50), Table 3, 
paper III. Hence, the association of IL28B genotype with spontaneous HCV clearance 
in co-infected patients was confirmed in our study [32].  
 
One limitation of this study is our definition of spontaneously cleared and chronic 
HCV, which might lead to misclassification. Acute HCV infection at the time of data 
extraction or the latest HCV RNA test would be misclassified as a chronic infection.  
HCV RNA sampling was performed according to the clinical routine and often there 
was only one sample available. However, the standard clinical definition of chronic 
HCV was applied. Since the majority of patients do not clear HCV spontaneously, this 
definition is mostly correct. Misclassification of acute HCV as chronic would lead to an 
underestimation of the rate of spontaneous clearance and a lower power to detect 
factors associated with clearance.   
This might affect clearance rates according to transmission routes differentially, but is 
likely to be non-differential with regards to HBsAg positivity and IL2B genotype.  
 
7.2.6 Three cases of spontaneous clearance of chronic HCV infection – 
association with IL28B genotype CC? (Paper III) 
Among our 263 IL28B genotype tested patients, 3 had spontaneously cleared their 
chronic HCV infection after immune reconstitution induced by ART. These individuals 
became HCV-RNA negative without specific HCV treatment after previously being 
diagnosed to have a chronic HCV infection with at least 2 positive HCV-RNA tests 6 
months apart. Their cases were briefly reported in paper III (Figure 1 a, b, c). All three 
patients had IL28B genotype CC.  
 
Since IL28B genotype CC was found in 122/263 tested patients, of whom 106 were on 
ART, these 3 cases make up 3/106 (2.8%) of our patients on ART harbouring genotype 
CC. If only tested patients with IL28B genotype CC, ART and chronic HCV are 
considered in the denominator, they would make up 3/68 (4.4%). If the IL28B 
genotype results, the HCV chronicity rate and the ART uptake were extrapolated to our 
total co-infected cohort the cases would make up 3/151 (2.0%). Hence, our three cases 
represents only 2-4% of all our IL28B genotype CC patients. This means that the 
spontaneous clearance of a chronic HCV is indeed a rare event.  
Our three cases were thoroughly verified, however, our methods do not rule out that 
there might be additional cases of spontaneous clearance of chronic HCV in our cohort.  
Our case 1c was found to have a low level of chronic T cell activation and a high level 
of T cell function as earlier published [232].  
   
This possible association with spontaneous clearance of chronic HCV underlines the 
importance of the favourable IL28B genotype CC. In a subset of patients with this 
genotype, thus spontaneous clearance of HCV can occur beyond the acute stage in the 
setting of ART induced immune recovery.   
In HIV/HCV co-infected patients with CD4+ T cell counts <350/microL, improvement 
of CD4+ T-cell counts using ART is recommended before HCV treatment is initiated 
to optimize the chance of SVR (EACS, guidelines 2013 v7.0, www.eacsociety.org). 
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ART has also been shown to slow down the rate of fibrosis progression. Taken together 
with our findings, we speculate that most, if not all, co-infected patients would benefit 
from early ART. Hence, ART should probably be started as soon as possible regardless 
of CD4+ T-cell count and precede the HCV treatment in HIV/HCV co-infected 
patients.      
A more direct implication of our finding is that HCV RNA testing should be done 
immediately before the initiation of HCV treatment, since a subset of HIV/HCV co-
infected patients may have cleared their chronic infection spontaneously.  
 
7.2.7 HCV treatment uptake (paper IV) 
The HCV treatment uptake (ever treated) in Sweden was 25% in 2010. This is in line 
with reports from the EuroSIDA cohort[218]. That cohort has the strengths of 
prospectively recorded data and huge size, but may actually overestimate the treatment 
uptake if the centres reporting to EuroSIDA are not representative of all centres in the 
respective countries.  
 
It may also be in line with the treatment rate in HCV mono-infected patients in 
Sweden, although firm statistics are lacking [15, 71]. If similar, this would be in 
contrast with previous reports, where co-infected patients were considered less likely to 
have initiated HCV treatment than mono-infected patients. This is perhaps also the 
clinical notion from the perspective of a HCV mono-infection department, where the 
majority of patients probably will initiate HCV treatment. However, as already pointed 
out, these patients are already highly selected and often HCV treatment motivated.  
HIV/HCV co-infected patients attend the HIV outpatient department mainly to receive 
health care for their HIV infection. Their attendance is mandatory by the 
Communicable Diseases Act and does not depend on their knowledge of and/or 
treatment motivation for the HCV infection.  
 
A major limitation of our study is that we do not have data on migrated or deceased 
HIV/HCV co-infected persons. Since HCV treated persons who achieve SVR have a 
lower risk of dying from HCV, this introduces a survival bias that may lead to an 
overestimation of the HCV treatment uptake if compared to prospective cohorts. The 
relative importance of liver related mortality in the Swedish HIV/HCV co-infected 
cohort has not been studied in detail.  
In PWID, chronic compared with cleared HCV infection was not associated with 
mortality in a Danish nation-wide cohort study, probably due to competing causes of 
death in persons with on-going IDU. The mortality, however, was higher among 
persons with chronic HCV infection with other HIV transmission routes[233]. In the 
larger EuroSIDA material a difference in liver related mortality between persons with 
chronic versus cleared HCV was also found. No stratification by HIV transmission 
route was reported, but the cohort included 23% PWID [126]. Among PWIDs 
surviving long enough to develop long term complications, the liver related morbidity 
and mortality is high[234, 235]. In total, 64% of our patients with chronic HCV were 
infected with HIV via IDU. However, data on active versus former IDU are lacking in 
InfCare HIV.    
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The HIV treatment rate, and rate of undetectable HIV viral load, indicate that many co-
infected patients who had not yet initiated HCV treatment were adherent to their HIV 
treatment. A discrepancy between treatment initiation for HIV and HCV was obvious, 
since many more had initiated ART than HCV treatment. Certainly, ART is more 
urgent and all patients will need ART eventually, whereas HCV treatment might be 
postponed or not needed for all patients if the rate of fibrosis progression is slow.  
 
7.2.8 Factors associated with initiation of HCV treatment (paper IV) 
Three factors were found to be associated with a higher HCV treatment rate: HIV 
transmission route other than IDU, HCV genotype 2 or 3, and on-going ART. (Table 1 
and 2, paper IV).   
 
The HCV treatment rate varied significantly according to HIV transmission route. 
Hence, it was 20% in PWID, 29% in heterosexuals, 38% in MSM and 44% in persons 
infected via blood transfusion (p<0.01) (Figure 5).   
MSM and persons who had acquired HIV infection via blood transfusion had increased 
odds of having initiated HCV treatment compared to PWID: aOR 2.60 (95% CI, 1.13-
5.92), p= 0.02 and aOR 3.24 (95% CI 1.23-8.59), p=0.02, respectively. When the 
analysis was repeated using anti-HCV positive persons as the denominator, instead of 
patients with confirmed chronic HCV, the results were similar (data not shown).  
The lower HCV treatment uptake among PWIDs compared to patients with other HIV 
transmission routes was most likely due to many factors, including on-going IDU, 
rending the provider less inclined to offer treatment for this group.   
For comparison, the HIV treatment rate in HIV/HCV co-infected patients according to 
HIV transmission route is also depicted in Figure 5. There was no significant difference 
in HIV treatment rate according to transmission route in the HIV/HCV co-infected 
cohort. A trend, however, was noted for persons who acquired their HIV infection via 
blood transfusion to have a higher HIV treatment rate than PWID.  
 
 
Figure 5. HIV (left bar) and HCV treatment uptake in % according to HIV transmission route 
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Patients with HCV genotype 2 or 3 had increased odds of having initiated HCV 
treatment when compared with patients with HCV genotype 1, 4, 5 or 6: aOR 2.19 
(95% CI. 1.33-3.65), p=0.0021. This was probably because of higher SVR rates and the 
short treatment duration. Patients with on-going ART also had increased odds of having 
initiated HCV treatment compared with ART naive patients: aOR 3.40 (95% CI 1.42-
9.56), p=0.0045. This could reflect their assumed better adherence to any treatment.  
 
The recently published EuroSIDA study on HCV treatment uptake also reported higher 
treatment rates in MSM versus PWID. In their study, HIV-RNA<500 copies/mL and 
CD4+ T-cell count >350 were associated with higher HCV treatment rates, probably 
indicating good adherence to ART. A higher proportion of their treated versus non-
treated patients had significant fibrosis (>F2). Unfortunately, no data on fibrosis stage 
are available in the InfCare HIV database. However, in contrast with our findings, they 
found no association between treatment rates and HCV genotype [218]. This is 
somewhat surprising, since the decision to initiate HCV treatment is usually based on 
weighing the individual’s chance of SVR, which is higher in HCV genotype 2/3, 
against the risks of HCV treatment.   
 
In our study, other demographic factors, including gender, ethnicity, university clinic or 
not were not significantly associated with HCV treatment initiation. 
The SVR rate was 31% in HCV genotype 1, 87% in genotype 2, and 70% in genotype 
3, which is comparable to those reported from large trials [186, 187, 192].   
 
7.2.9 Barriers to HCV treatment  (Paper IV) 
The results of the questionnaires are depicted in Figure 6. Stated reasons for not having 
initiated HCV treatment by a) HIV/HCV co-infected patients (n=114), b) physicians 
(n=210), c) HIV/HCV co-infected PWIDs only (n=95) and d) physicians corresponding 
to 6c (n=95) are shown.  
For details on the Stockholm cohort, response rates and a comparison of responders 
versus non-responders, see paper IV.  
According to the questionnaires, the main barrier to HCV treatment in HIV/HCV co-
infected patients was IDU/alcohol abuse. Very few had somatic contraindications, and 
only one patient could not be treated because of AIDS.   
In contrast, the results from the HCV mono-infected patients highlighted the 
importance of the attending doctor’s recommendation, stated by 52% of patients and 
62% of physicians. Since HCV mono-infected patients are already selected when 
attending the outpatient department of an infectious diseases clinic, these two 
populations cannot readily be compared. For example, only one (1.3%) of the mono-
infected patients reported recent IDU, vs. 46% of the co-infected patients. We therefore 
decided not to include the results of HCV mono-infected patients and their physicians 
in paper IV.  
 
In this well-defined cohort of non-treated patients the response rate in HIV/HCV co-
infected patients was low (55%). This is a major limitation of the questionnaire-based 
sub-study. Non-responders were more likely to be born outside of Sweden, thus poor 
Swedish might have hindered participation. Also, non-responders were less likely to be 
on ART, which could indicate poor adherence or a recent HIV diagnosis.  
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Figure 6. Reasons stated for not having initiated HCV treatment  
by a) co-infected patients b) physicians c) PWIDs d) physicians corresponding to 6c 
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The response rate of the physicians was high (88%). Other studies may include only the 
opinion of the attending physician, or are based on retrospective charts review[67]. 
According to our results, patients and physician stated reasons are not always in 
agreement (Figure 6, c-d). Other qualitative research methods, such as focus group 
discussions, might be considered in order to explore the causes of non-treatment from 
the patient´s perspective.    
 
In a recent publication, system-, practitioner- and patient-level barriers to HCV care in 
HIV/HCV co-infected patients were reviewed [236]. The dominating cause of non-
treatment in our study, on-going or recent drug abuse, can be interpreted as mainly a 
practitioner-level barrier but also a patient-level barrier, since both physicians and 
patients seemed to regard this as an absolute contra-indication for HCV treatment. 
Interestingly, many patients with on-going IDU stated that they would accept HCV 
treatment if offered. However, other patient-level barriers such as low perceived need 
for HCV treatment, fear of side effects and unstable housing were also important. 
 
With the new DAAs, the treatment duration will be shorter and side effects much less 
pronounced. Hence, there may be increased possibilities to treat PWID even though 
their risk of reinfection must be taken into account. Mathematical modelling suggests 
that increasing HCV treatment uptake of this group could have an impact on the HCV 
epidemic and even be cost-effective [65, 66]. The cost of HCV treatment will, however, 
remain an obstacle for a broader treatment uptake.   
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8 CONCLUSIONS 
 
The IL28B genotype CC was associated with a higher baseline HCV RNA viral load 
and a steeper first phase decline during peg-IFN+RBV treatment in HCV genotype 2/3 
mono-infected patients. However, this did not translate into higher rates of SVR. The 
importance of pre-treatment IL28B can thus be questioned in patients with HCV 
genotype 2/3 planning interferon-based HCV treatment. The small number of 
HIV/HCV co-infected patients included in the treatment study prevents firm 
conclusions to be drawn. (Paper II) 
 
IL28B genotype CC was strongly associated with spontaneous clearance of acute HCV 
in HIV/HCV co-infected patients. Also, three cases of spontaneous clearance of 
chronic HCV after immune reconstitution induced by ART were noted, all with 
genotype CC. This finding, although rare (about 2-4% of the cohort), underlines the 
importance of Il28B genotype CC and lends some support to the initiation of ART 
before HCV treatment in co-infected patients. It also indicates that HCV-RNA testing 
should be done prior to initiating HCV treatment in HIV/HCV co-infected patients.  
Among other investigated baseline factors, only a chronic HBV infection was 
associated with spontaneous clearance of HCV. (Paper III) 
 
The prevalence of anti-HCV in the total HIV infected Swedish cohort was 14% in 
2010. This corresponds to a 9-11% prevalence of chronic HCV. This is low by 
international comparison and lower than previously reported[119]. A probable reason is 
the distribution of HIV transmission routes in the Swedish HIV infected cohort, where 
IDU is relatively rare (8%). HCV genotype 1, mostly 1a, dominates.  (Paper III and IV) 
 
The cumulative HCV treatment uptake in the HIV/HCV co-infected cohort in Sweden 
2010 was 25%. This is in line with treatment uptake reported from Europe, and may 
also be in line with published data on treatment uptake in HCV mono-infected patients 
in Sweden[15, 71, 218]. If so, this would contradict previous reports of HIV/HCV co-
infected persons having lower access to HCV treatment than HCV mono-infected 
patients. (Paper IV) 
 
The HCV treatment rate was higher in patients with HCV genotype 2/3, HIV 
transmission route other than IDU and on-going ART.  Interestingly, no differences in 
HCV treatment rate based on gender, ethnicity or treatment facility were found. 
A major reason for not having initiated HCV treatment was on-going or recent IDU. 
(Paper IV) 
 
The higher HIV treatment rate, and rate of undetectable HIV viral load, indicate that 
many patients who had not initiated HCV treatment were adherent to their HIV 
treatment. When interferon-free DAA combinations soon will become available, HCV 
treatment should expand to include more HIV/HCV co-infected patients in order to 
prevent morbidity and mortality from HCV in this population.  (Paper IV)  
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SUMMARY. The IL28 gene is highly associated with sus-
tained viral response (SVR) in patients infected with geno-
type 1 after standard of care (SOC) treatment with peg-IFN
and ribavirin. It is also associated with a steeper first phase
HCV RNA decline during treatment. In genotype 2 and 3
infections, these correlations are less obvious. We studied
the IL28B association to rapid viral response (RVR), SVR,
first and second phase HCV RNA decline during treatment
in 100 HCV mono-infected and 13 HCV/HIV co-infected
patients. We found a significantly higher mean baseline
HCV RNA level in IL28B SNP CC than non-CC mono-
infected patients, 6.99 vs 6.30 log10 IU/mL (P = 0.02),
and a significantly larger median 1st phase decline in
patients with CC than non-CC genotype, 2.03 vs 1.37
log10 IU/mL, respectively. The overall SVR rate in HCV
mono-infected patients was 87% vs 77% in HCV/HIV
co-infected patients, with no correlation to IL28B SNP. In
mono-infected patients with RVR, the SVR rate was high
and independent of IL28B genotype. In mono-infected
patients who failed to achieve RVR who had IL28B CC and
non-CC genotype, 64% and 67% achieved SVR, respec-
tively. In genotype 2 and 3 infected patients, the 1st phase
HCV RNA decline was steeper in patients with IL28B CC vs
non-CC genotype during SOC treatment. This did not
translate into a higher frequency of RVR or SVR. Hence,
the clinical relevance of pretreatment analysis of IL28B
polymorphisms in genotype 2 and 3 infected patients can
be questioned in patients with expected high SVR rate.
Keywords: HCV RNA, Hepatitis C virus, IL28B, peg-IFN,
ribavirin.
INTRODUCTION
Hepatitis C (HCV) is a major cause of morbidity and
mortality in HCV mono-infected and HCV/HIV co-infected
patients [1,2]. In those who achieve sustained viral
response (SVR) with standard of care treatment (SOC) with
peg-interferon (peg-IFN) and ribavirin (RBV), the long-term
outcome is improved [3]. The current HCV treatment,
however, is associated with frequent side effects, a high
cost, and the access to treatment is variable, and only a
minority of HCV/HIV co-infected patients are offered
SOC treatment [4]. To promote treatment further, identifi-
cation of the patient who is most likely to respond is
important.
Several important factors predictive of SOC treatment
response such as age, fibrosis stage, genotype and viral
load are well known [5,6].
Recently, the single-nucleotide polymorphism (SNP),
rs12979860, near the IL28B gene (coding for IFN-
lambda-3) has shown a strong association with SVR
after SOC treatment both in HCV mono-infected and
HCV/HIV co-infected genotype 1 patients [7–9]. The
IL28B SNP also correlates with a faster 1st and 2nd
phase decline of the viral load during SOC treatment
in genotype 1 infections and a more frequent rapid
viral response (RVR) rate [10]. In genotype 2 and 3
infected patients, this association seems to be less pro-
nounced [11–14]. Hence, IL28B correlation to RVR
and non-RVR has yielded divergent results [11–13,15].
In this study, the correlation of the IL28B SNP and
HCV RNA decline during the 1st and 2nd phase of
SOC treatment in genotypes 2 and 3 infected HCV
patients was studied, in both HCV mono- and HCV/
HIV co-infected patients. We also correlated the
IL28B gene polymorphism to RVR and SVR in these
patients.
Abbreviations: APRI, ASAT to platelet ratio; ART, antiretroviral
treatment; cEVR, Complete early viral response; ETR, end of
treatment response; EVR, early viral response; GUCI, Gothenburg
University Cirrhosis Index; HCV, hepatitis C virus; peg-IFN, peg-
interferon; RBV, ribavirin; RVR, rapid viral response; SNP, single
nucleotide polymorphism; SOC, standard of care; SVR, sustained
viral response.
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MATERIAL AND METHODS
Patients were recruited at the Karolinska University Hospi-
tal Huddinge, Stockholm, Sweden, as described earlier [16–
18]. In total, 100 consecutive HCV mono-infected and 13
HCV/HIV co-infected naive genotype 2 or 3 patients were
studied. Patients with chronic hepatitis B, other concomi-
tant liver diseases, ongoing substance abuse or severe
psychiatric disease were excluded.
Ten of 13 co-infected patients had had undetectable HIV
RNA levels on antiretroviral treatment (ART) for a mini-
mum of 6 months prior to inclusion. Three co-infected
patients had not yet initiated ART, all with CD4 T-cell
counts above 350.
Liver biopsies are not performed in genotype 2 and 3
infected patients according to the Swedish consensus
guidelines, which allows treatment without histological
evaluation.
Gothenburg University Cirrhosis Index (GUCI) and ASAT
to platelet ratio (APRI) scores were used to have an estimate
if advanced or nonadvanced stage of fibrosis was at hand.
Hepatitis C treatment
All patients were treated with SOC consisting of peg-IFN
alpha-2a (Pegasys, Welwyn Garden City, UK) 135 lg/week
and RBV (Copegus, Roche AB, Stockholm, Sweden) 11 mg/
kg/day during 24 weeks according to Swedish consensus
guidelines [19].
Ninety-seven percentage of mono-infected and all co-infected
patients completed a full 24 weeks treatment course.
Virological methods
Hepatitis C virus-RNA levels were measured at baseline, day
2, week 1, 2, 4, 12, 24 and week 48 and analysed by Roche
Taqman Real-Time PCR (detection limit of 15 IU/mL) [20].
Hepatitis C virus genotyping was performed with a line
probe assay (Inno-LiPA HCV II, Innogenetics NV, Gent,
Belgium) or an in-house method [21].
rs12979860 SNP genotyping
Genotyping for the IL28B rs12979860 SNP was performed
with an in-house Taqman-based allele-specific PCR method
on DNA extracted from frozen EDTA plasma. The SNP was
defined as rs12979860 genotype CC, CT or TT.
The following primers and probes were used: rs12979860
forward, GCCTGTCGTGTACTGAACCA; rs12979860 reverse,
GCGCGGAGTGCAATTCAAC; probe C, FAM-CTGGTTACGCCTTC-
MGB; probe T, VIC-TGGTTCGCGCCTTC-MGB.
HCV RNA decline
The viral decline was analysed during the 1st phase, defined
as the decline in HCV RNA levels from baseline to treatment
day 2, and 2nd phase as the decline in HCV RNA levels
from HCV RNA day 2 to treatment week 2 or 4. RVR was
defined as negative (<15 IU/mL) HCV RNA at week 4. Com-
plete early viral response (cEVR) was defined as negative
HCV RNA week 12. Partial EVR (pEVR) was defined as at
least a 2 log 10 drop in HCV-RNA levels from baseline to
treatment week 12. Patients who failed to achieve pEVR
stopped treatment. End of treatment response (ETR) was
defined as negative HCV RNA at treatment cessation (week
24) and SVR also at 6-month follow-up after treatment.
Statistics
The primary end point was to study whether the 1st and
2nd phase HCV RNA decline in mono- and in co-infected
patients varied according to IL28B genotype CC or CT/TT
(non-CC).
Furthermore, the absolute HCV-RNA values at baseline,
day 2, week 1, 2 and 4 were analysed according to CC or
CT/TT (non-CC) genotype.
Hepatitis C virus RNA levels of < 15 IU/mL were set to
14 IU/mL for statistical analysis.
The chi-square test or Fisher’s exact two-tailed test was
used to test categorical variables.
The Wilcoxon rank sum test was used for continuous
variables. A P-value <0.05 was judged to be statistically
significant.
Ethics
The study was performed in accordance with the Helsinki
declaration and was approved by The Local Ethics commit-
tee. The study persons gave their informed written con-
sent.
RESULTS
Demographics
Mono-infected: A total of 100 consecutive HCV mono-
infected patients treated with SOC were included. A major-
ity (94%) of our patients were Caucasians. There were 48
males (48%) with a median age of 45 years. HCV genotype
3 was seen in 59%. Overall the baseline median HCV RNA
was 6.67 log 10 IU/mL.
An estimate of the fibrosis stage (advanced vs nonad-
vanced) was made based on the duration of the HCV infec-
tion, and by the APRI and GUCI fibrosis scores [22,23].
The median disease duration was 23 years. The median
GUCI score was 0.58 in mono-infected patients. The APRI
scores were not significantly different in any patient group.
Co-infected patients: A total of 13 HCV/HIV co-infected
with a mean age of 51 years were treated and included,
whereof 85% were Caucasians. Of these 11 (85%) were
males. HCV genotype 3 was found in 69%. Overall the
© 2012 Blackwell Publishing Ltd
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baseline median HCV RNA was 6.49 log 10 IU/mL. The
median disease duration was 31 years, and not different
from that in mono-infected patients (P = ns). The median
GUCI score was 0.71.
The baseline demographics according to IL28B genotype
CC vs non-CC in HCV mono- and HCV/HIV co-infected
patients are given in Table 1.
The baseline median HCV RNA in HCV mono-infected
patients with the IL28B CC genotype was significantly
higher than in patients with the non-CC group;
9 750 000 IU/mL (6.99 log10 IU/mL) vs 2 000 000 IU/
mL (6.33 log10 IU/mL), respectively, P = 0.02.
Prevalence of rs12979860 genotypes in the study
population according to HCV genotype
In the 100 mono-infected patients, the overall prevalence
of the rs12979860 genotype CC, CT and TT was 44%,
52% and 4%, respectively. The corresponding figures in
genotype 2 infected patients were 43%, 55% and 3%, and
46%, 49% and 5% in genotype 3 infected, respectively. In
the co-infected patients, the corresponding figures were
46%, 46% and 8%, respectively.
Overall HCV RNA 1st and 2nd phase decline according
to rs12979860 genotype
The overall HCV RNA decline during the 1st and 2nd
phase decline according to the rs12979860 IL28B geno-
type in HCV mono- and HCV/HIV co-infected patients is
given in Table 2 and Fig. 1. This difference was not seen
in the co-infected patients because of the small number of
patients included (Table 2).
The absolute median HCV-RNA levels (log10 IU/mL) at dif-
ferent time points during the first 4 weeks of SOC treatment
according to IL28B genotype are depicted for HCV mono-
infected patients in Fig. 2a, and for the 13 HCV/HIV co-
infected patients, the individual HCV-RNA levels according to
IL28B genotype CC and non-CC patients are given in Fig. 2b.
1st phase HCV RNA decline during SOC treatment
In the HCV mono-infected patients, the median decline in
HCV RNA level from baseline to day 2 (1st phase decline)
was significantly higher for patients with the CC than non-
CC genotype, 2.03 vs 1.37 log10 IU/mL, respectively
(P = 0.01, Figs 1 & 2a).
Table 1 Baseline demographics in HCV genotype 2 or 3 mono- and HCV/HIV co-infected patients according to IL28B CC
or non-CC genotype
HCV mono-infected HCV/HIV co-infected
CC (n = 44) Non-CC (n = 55) CC (n = 6) Non-CC (n = 7)
Age, median (range) 44 (22–63) 45 (20–69) 50 (38–56) 51 (40–62)
Gender M/F 19/25 28/27 5/1 6/1
Race White/Asian/Other 43/0/1 51/0/4 5/1/0 6/0/1
Weight kg, median (range) 75 (48–105) 75 (50–109) 72 (57–90) 75 (65–96)
BMI kg/m2, median (range) 26 (18–36) 24 (30–35) 22 (18–26) 25 (21–29)
Transmission
i.v. drug abuse 30 37 6 6
Transfusion 4 4 0 1
Sporadic 10 14 0 0
Duration of HCV infection years,
median (range)
24 (4–52) 22 (2–43) 29 (19–36) 32 (29–35)
HCV RNA IU/mL*, median
(range)
9.75 M
(0.0015–69 M)
2.0 M
(0.0071–50 M)
1.55 M
(0.89–22.7 M)
6.2 M
(0.90–10.2 M)
HCV genotype 2/3 17/27 23/32 2/4 2/5
ALT ukat/L, median (range)
(Upper limit
of normal: 0.70)
1.6 (0.3–6.2) 1.1 (0.3–3.8) 1.5 (0.7–4.3) 1.0 (0.4–1.7)
APRI score, median (range) 0.73 (0.26–3.29) 0.58 (0.19–5.05) 1.17 (0.46–5.40) 0.48 (0.30–2.24)
GUCI score, median (range) 0.78 (0.26–3.95) 0.49 (0.18–6.08) 2.04 (0.50–6.48) 0.63 (0.33–2.46)
CD4+ T-cells/lL blood,
median (range)
– – 367 (301–498) 743 (310–858)
On antiretroviral therapy
(including abacavir)
– – 4/6 (1/6) 6/7 (2/7)
*Assay: Roche Taqman Real-Time PCR.
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The corresponding figures in the co-infected patients
were 1.49 and 1.30 log10 IU/mL, respectively, for patients
with the CC and non-CC (P = 0.78, ns, Figs 1 & 2b).
2nd phase HCV RNA decline during SOC treatment
In the HCV mono-infected patients, the median decline in
HCV RNA level from day 2 to week 2 reflecting the 2nd
phase decline was 2.00 and 1.58 log10 IU/mL in patients
with the CC and CT/TT genotype, respectively (P = 0.11,
ns, Figs 1 & 2a).
In the co-infected patients, the corresponding figures were
2.50 vs 0.94 log10 IU/mL (P = 0.20, ns, Figs 1 & 2b).
In the HCV mono-infected patients, the median decline
in HCV RNA level from day 2 to week 4, also reflecting
the 2nd phase decline, was 3.60 and 3.22 log10 IU/mL,
respectively, in patients with the IL28B CC and non-CC
genotype (P = 0.14, ns).
In the HCV/HIV co-infected patients, the corresponding
figures were 3.10 vs 2.62 log10 IU/mL (P = 0.15, ns). The
individual HCV RNA levels during the first 4 weeks treat-
ment in the HCV/HIV co-infected patients are given in Fig. 2
panel c and d according to IL28B genotype CC vs non-CC.
RVR and SVR during SOC treatment according to
IL28B genotype
RVR and SVR in mono-infected patients according to
IL28B genotype are shown in Fig. 3.
The proportion of patients with RVR in mono-infected
patients with CC was 74% vs 67% in patients with non-CC
SNP (P = 0.41, ns). In HCV/HIV co-infected patients, the
corresponding figures were 67% vs 29% (P = 0.17, ns).
In mono-infected patients achieving RVR, the proportion
of patients with SVR was high (97%) and independent of
rs12979860 genotype.
In mono-infected patients failing to achieve RVR, 64%
and 67% with IL28B CC and CT/TT genotype, respectively,
achieved SVR (data not shown).
Table 2 Mean baseline HCV RNA and HCV RNA decline
(log10 IU/mL) during the 1st and 2nd phase decline in
mono- and HCV/HIV co-infected patients with genotype 2
and 3 according to IL28B CC or non-CC genotype
Mono-infected,
n = 99 P-value
Co-infected,
n = 13 P-value
HCV RNA baseline
CC 6.99 0.02 6.20 0.95
Non-CC 6.30 6.79
1st phase decline
CC 2.03 0.01 1.49 0.78
Non-CC 1.37 1.30
2nd phase (d2-w2)
CC 2.00 0.11 2.50 0.20
Non-CC 1.58 0.94
2nd phase (d2-w4)
CC 3.60 0.14 3.10 0.15
Non-CC 3.22 2.62
P < 0.02 P < 0.01
P = 0.11
(a)
(c)
(b)
Fig. 1 Boxplot of HCV RNA levels at baseline and during the 1st and 2nd phase viral decline during SOC treatment according
to IL28B SNP CC or non-CC in HCV genotype 2 and 3 mono-infected patients (n = 99). The lower and upper bar in the box
depicts the 25th and 75th percentile, respectively. SOC, standard of care treatment consisting of peg-IFN and ribavirin. Panel
(a) baseline HCV RNA levels (log10). Panel (b) log10 HCV RNA decline from baseline to day 2 (reflecting the 1st phase decline).
Panel (c) log10 HCV RNA decline from day 2 to week 2 (reflecting the 2nd phase decline).
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The overall SVR rate in HCV mono-infected patients was
86/99 (87%) vs 10/13 (77%) in HCV/HIV co-infected
patients and did not differ according to IL28B SNP.
Furthermore, separate analyses of the RVR and SVR rates
in genotype 2 and 3 infected patients did not reveal
any significant difference according to IL28B genotype
(Fig. 3).
The influence of baseline factors such as disease duration,
gender, weight, baseline HCV RNA viral load, APRI score as
surrogate marker for fibrosis, genotype 2 vs 3 and IL28B SNP
CC vs non-CC on RVR and SVR was analysed. In the univari-
ate analyses, no baseline factor was significantly correlated to
SVR and only disease duration to RVR (P = 0.04). Baseline
HCV RNA was nearly significantly associated with RVR
(P = 0.057). As no baseline factor was significantly associ-
ated with SVR, no multivariate analysis was performed.
DISCUSSION
In this study, we found a significantly steeper 1st phase
HCV RNA decline during standard of care treatment in
genotype 2 and 3 mono-infected HCV patients with CC vs
CT/TT rs12979860 genotype as recently noted by others
in genotype 3 infected [14] and genotype 2 and 3 infected
patients [11]. A trend towards a more steep 2nd phase
decline was also seen in patients with the CC rs12979860
vs non-CC genotype; however, this was not significant.
Concerning RVR, however, we found no significant associ-
ation with the rs12979860 genotype. This possibly reflects
the high response rate seen with SOC treatment in geno-
type 2 and 3 infected patients. Findings in other studies
with larger number of genotype 2 or 3 infected patients
have yielded conflicting results on the influence of IL28B
genotype on RVR rate [12–15,24]. RVR, however, had a
high probability of achieving SVR [18].
In our co-infected group, there was no significant differ-
ence in HCV RNA kinetics or in the frequency of RVR and
SVR. The power to detect such differences, however, was
low because of the small number of co-infected persons
included.
In an Italian study of mainly genotype 2 infected
patients, Mangia et al. found a significant association with
SVR and the IL28B genotype CC in patients lacking RVR
but not in patients with RVR [12]. In this study, a trend
HCV mono-infected (n = 99) HCV/HIV co-infected (n = 13) 
HCV/HIV co-infected CC (n = 6) HCV/HIV co-infected non CC (n = 7)
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Fig. 2 Median HCV RNA (log10 IU/mL) levels at baseline, day 2, week 1, 2 and 4 during SOC treatment according to
IL28B genotype in HCV genotype 2 and 3 mono-infected and HCV/HIV co-infected patients. SOC, standard of care
treatment consisting of peg-IFN and ribavirin. Panel (a) Mean HCV RNA (log10 IU/mL) levels in HCV mono-infected
patients. Panel (b) Mean HCV RNA (log10 IU/mL) levels in HCV/HIV co-infected patients. Panel (c) Individual HCV RNA
(log10 IU/mL) levels in HCV/HIV co-infected patients with IL28B CC genotype. Panel (d) Individual HCV RNA (log10 IU/
mL) levels in HCV/HIV co-infected patients with IL28B non-CC genotype.
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towards higher baseline HCV RNA viral load was reported
in patients with the CC genotype. In the study of Mangia
et al., however, few patients with HCV infection caused by
genotype 3 were included. In the study by Moghaddam
et al. on the contrary, the majority of patients included
were infected with genotype 3 and these authors found a
significant association with RVR but not SVR in patients
with the CC genotype [15].
In a German study, Sarrazin et al. reported an associa-
tion with SVR but not with RVR in IL28B CC genotype
patients with both genotype 2 and 3 [13]. In this study, a
significant association with higher baseline HCV-RNA viral
load was seen in CC patients with genotype 2 and 3 as has
previously been described in genotype 1 infected patients
[7,10,11].
In our study, we found a significant steeper 1st
phase HCV RNA decline in genotype 2 and 3 infected
patients with the CC genotype than in patients with the
non-CC genotypes in line with what has recently been
shown in another Swedish study [11]. We did, however,
not find a higher RVR or SVR rate. Our findings were
probably caused by the high response rate seen in our
genotype 2 and 3 patients, meaning that small differences
cannot be discerned. For this, larger patient numbers are
needed.
In another recent Scandinavian study mainly consisting
of genotype 3 patients, however, the IL28B CC genotype
was associated with RVR but not with SVR [15]. We found
that the SVR rate among our patients was similar in
genotype 2 and 3 infected patients as was the RVR rate
[18]. Thus, RVR was seen in 70% of our patients and
SVR in more than 95% of those achieving RVR, irrespec-
tive of whether they were infected with genotype 2 or 3
[18].
To conclude, we found that the 1st phase HCV RNA
decline was steeper in patients with IL28B CC vs in non-CC
genotype during standard of care treatment in genotype 2
and 3 infected patients, but that this did not translate into
a higher frequency of RVR or SVR. Small differences might
be seen in studies including large patient numbers, but
the clinical relevance of pretreatment analysis of IL28B
genotypes in genotype 2 and 3 infected patients can be
questioned because these patients are expected to have
high SVR rates anyway.
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Abstract 
 
Background and aims 
The IL28B genotype correlates with spontaneous clearance of acute hepatitis 
C virus (HCV), and with sustained viral response to peg-IFN plus ribavirin 
treatment.  
Here, we report on three cases of spontaneous resolution of a chronic HCV 
infection in HIV/HCV co-infected patients after ART induced immune 
reconstitution. Furthermore, the correlation of IL28B genotype and baseline 
demographical factors with spontaneous HCV clearance was analyzed in the 
total Swedish HIV/HCV co-infected cohort, from which the three cases were 
derived.  
 
Methods 
Among all 5315 Swedish HIV infected patients in September 2010, 
demographical data from 652 HIV/HCV co-infected patients were extracted. 
Spontaneous clearance of HCV was defined as a positive anti-HCV test but a 
negative HCV-RNA test in the absence of HCV treatment.  
A subset of 263 anti-HCV positive patients was tested for IL28B genotype.  
 
Results  
Three patients with chronic HCV had spontaneously cleared their HCV 
infection after ART, all with IL28B genotype CC. These cases make up 2-4% 
of all our HIV/HCV co-infected patients on ART with genotype CC.  
The IL28B genotype CC was also found to have a strong correlation with a 
spontaneous HCV clearance. Thus, 36% of patients with the CC versus 13% 
with the non-CC genotype had cleared their acute HCV infection, p=0.0004, 
OR 5.02 (2.11-12.92). Among other baseline factors, only a chronic hepatitis 
B infection was associated with spontaneous clearance of HCV.  
In total 14% of Swedish HIV positive patients were anti-HCV positive whereof 
79% also were HCV RNA positive.   
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Conclusions  
We found that immune reconstitution with ART occasionally can induce HCV 
clearance in HIV/HCV co-infected patients with established chronic HCV in 
patients with IL28B genotype CC. Spontaneous clearance of a HCV infection 
is strongly correlated with IL28B genotype CC.  
 
Key words 
HIV/HCV co-infection, spontaneous HCV clearance, IL28B genotype, immune 
reconstitution, ART 
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Introduction 
 
Chronic hepatitis C virus (HCV) infection affects more than 170 million 
persons worldwide and put them at risk of developing end stage liver disease 
and hepatocellular carcinoma (HCC) [1].  Acute HCV in HCV mono-infected 
individuals is spontaneously cleared in 15-40%, but the majority will go on to a 
chronic infection [2]. A lower rate of spontaneous HCV clearance of an acute 
infection is generally seen in patients with HIV infection than in HCV mono-
infected individuals [3].    
 
HIV/ HCV co-infection is common in many individuals due to shared routes of 
transmission. Hence, a total anti-HCV prevalence of 15-30% has been noted 
in HIV positive persons [4].  The prevalence, however, is dependent on the 
mode of HIV acquisition, and thus varies in different cohorts, countries, and 
epidemiological settings. People who inject drugs (PWID) are generally noted 
to have the highest HCV prevalence[4-9]  
 
The IL28B genotype has been found to have a strong influence on the 
sustained viral response rate to pegylated interferon (peg-IFN) plus ribavirin 
treatment, and to spontaneous clearance of HCV both in HCV mono- and 
HIV/HCV co-infected patients [10-16]. 
Demographical factors, such as gender and hepatitis B infection, have also 
been associated with spontaneous clearance of HCV both in HCV mono- and 
HIV/HCV co-infected persons [17-21]  
 
In Sweden, all known HIV/HCV co-infected patients have been included in a 
database (InfCare HIV) in which demographical, virological and treatment 
data are recorded. In this database studies largely devoid of selection bias 
can be done since it includes the total Swedish cohort.  
 
Here, we analyzed the spontaneous clearance rate of HCV in HIV/HCV co-
infected patients in this cohort. We also determined the IL28B genotype in a 
subgroup and correlated it with spontaneous clearance of HCV.  
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Spontaneous clearance of chronic HCV is a rare event but case reports in co-
infected patients without HCV therapy have been published [22-32]). We 
report on three such cases.  
 
 
Patients and methods 
 
Inclusion of patients 
On the 28th of September 2010, 5315 adult living persons were known to be 
HIV infected in Sweden. According to the Swedish law of communicable 
diseases all HIV infected patients are required to keep a regular contact with 
their health care provider (an Infectious Diseases or 
Dermatology/Venereology specialist).  All known HIV positive patients in 
Stockholm and Gothenburg have been prospectively included in the InfCare 
HIV research database since 2003, and all patients living in Sweden since 
2009. Retrospective data from the beginning of the 1990-s have also been 
included on patients from Stockholm and Gothenburg.  
 
Demographical data of all 652 living anti-HCV and anti-HIV positive adults, 18 
years of age or older, were extracted. Age, sex, ethnicity, HIV transmission 
route, clinical data, prior AIDS diagnosis, CD4+ T-cell count, virological data 
(anti-HCV serology, HCV-RNA levels, HCV genotype, HIV-RNA levels, HBV 
serology), and HCV and/or HIV treatment data were collected. Five patients 
who had received HCV treatment for acute hepatitis C were excluded from the 
analysis of factors associated with spontaneous clearance of HCV.   
Spontaneous clearance of HCV was defined as a positive anti-HCV test but a 
negative HCV-RNA test in a HCV treatment naïve patient. Chronic hepatitis C 
was defined as a positive HCV-RNA test. Hepatitis B infection was defined as 
a positive HBsAg test. 
 
Analysis of markers for HIV, HCV and HBV 
Analyses of HIV-RNA, anti-HCV antibodies, and HBV serology were 
performed utilizing routine techniques at the local virological laboratories. 
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HCV RNA was analyzed in anti-HCV positive individuals with the Roche 
TaqMan Test (detection limit of 15 IU/mL). HCV genotyping was performed 
with a line probe assay or an in-house method.  
 
IL28B genotyping 
Anti-HCV positive patients from the Stockholm area (n=263) were tested for 
IL28B rs 12979860 SNP with a Taqman-based allele-specific PCR method 
(Applied Biosystems Inc, Foster City, CA,USA), using the ABI 7500 Fast 
equipment. Human DNA was extracted from plasma obtained from EDTA 
blood kept at -70C. Human genomic DNA was purified from 500 µL of plasma 
and performed according to manufacturer’s instructions using the QIAamp 
DNA Mini kit (Qiagen, Tokyo, Japan), except for one change in the elution 
step; elution was done using 25 µL elution-buffer.  
 
All TaqMan probes and primers were designed and synthesised by Applied 
Biosystems Inc. Automated allele calling was performed using SDS software 
from Applied Biosystems. The primers and probes used were: rs12979860 
Forward primer: 5´GCCTGTCGTGTACTGAACCA3´, Reverse primer: 
5´GCGCGGAGTGCAATTCAAC3´, Vic probe: 5´TGGTTCGCGCCTTC3´, 
Fam probe: 5´CTGGTTCACGCCTTC3´.  
The SNP was defined as rs 12979860 genotype CC, CT or TT genotype.  
 
Statistics 
Differences between groups were compared with chi-square test for 
categorical variables and the Wilcoxon Rank Sum test for continuous 
variables. In the univariate model we included age, sex, ethnicity, HIV 
transmission route, prior AIDS diagnosis, CD4+ T-cell cell count, present 
ART, plasma HIV-RNA level, HBsAg status, and IL28B genotype. Factors with 
a p-value <0.10 were included in a multivariate model. Logistic regression 
was used to identify variables associated with spontaneous HCV clearance. 
The results are presented as odds ratio (OR) and adjusted OR (aOR) with 
95% confidence intervals (CI).  A p-value of < 0.05 was considered 
statistically significant.  All data were analyzed using JMP software version 
9.0.0.  
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Ethics 
The study was performed in accordance with the Declaration of Helsinki and 
was approved by the Regional Ethics committee (Dnr 2010/1782-31).  
 
Results 
 
Anti-HCV and HCV-RNA prevalence in the total Swedish HIV population 
An anti-HCV result was available in 4765/5315 (90%) known HIV infected 
persons. In total 14% were anti-HCV positive whereof 92% had been tested 
for HCV RNA. A chronic hepatitis C infection was diagnosed in 79% whereas 
21% spontaneously had cleared their HCV infection (Table 1). 
 
No anti-HCV test result was available in 550 (10%) patients. In this group, 
46% were females versus 36% in the anti-HCV tested group. The 
corresponding figures for PWID were 2.2% versus 8.6%, MSM (men who 
have sex with men) 28% versus 34%, and for patients with prior AIDS 
diagnosis 9.6% versus 16%, (p<0.05 for all comparisons). There was no 
significant difference in age or ethnicity between anti-HCV tested and non-
tested (data not shown).   
 
Anti-HCV positive patients who had not been tested for HCV RNA (n=54) 
were more likely to be ART naive than tested, 30% versus 15%, p<0.01. No 
significant difference in sex, age, risk group or ethnicity was noted between 
tested and not tested individuals (data not shown).    
 
 
Factors associated with spontaneous clearance of HCV 
Demographical data according to spontaneous clearance of HCV or not in the 
593 Swedish HIV/HCV positive individuals tested for HCV-RNA are depicted 
in Table 2.  In univariate analysis, the only factor significantly correlated with 
spontaneous clearance of HCV was HBsAg positivity. Eight of 16 patients 
(50%) with a positive HBsAg test versus 118/559 (21%) with a negative test 
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had spontaneously cleared HCV, odds ratio (OR) 14.7 (2.47-98.1), p=0.006, 
Table 2.  
In the multivariate analysis adjusted for sex and route of transmission an 
adjusted odds ratio (aOR) of 17.3 (2.42-125.6), p=0.003 for spontaneous 
clearance of HCV was seen in HBsAg- positive versus -negative persons 
(data not shown).  Five out of the 16 HBsAg positive patients were born in 
HBV intermediate to high endemic countries (Somalia, Burundi, Russia, Iran, 
Thailand) [33]. 
 
Spontaneous HCV clearance was seen in 26% females and 19% males, 
p=0.0563. The HCV clearance rate in persons who had been HIV infected via 
blood transfusions was 29%, via heterosexual contacts 28%, via IDUs 20%, 
and via homosexual contacts 16%. A difference was noted in clearance rate 
in heterosexuals versus IDUs approaching significance, p=0.0546 (Table 2).   
No significant difference was seen in the rate of spontaneous HCV clearance 
in persons with ongoing ART (22%) versus in ART naïve persons (14%), 
p=0.10. In total 79% of the anti-HCV positive patients had ongoing ART at the 
time of data extraction (Table 2).  
 
 
IL28B correlation with spontaneous HCV clearance 
IL28B genotyping was performed in 263 anti-HCV positive patients followed at 
the Karolinska University Hospital. Their demographics and IL28B distribution 
are depicted in Table 3.     
 
The following IL28B genotype distribution was found: 46% CC, 43% CT and 
11% TT.  A strong correlation between IL28B genotype and spontaneous 
HCV clearance was noted. Thus, 36% of individuals with CC versus only 13% 
with non-CC had spontaneously cleared their HCV infection, p=0.0004, OR 
5.02 (2.11-12.92), Table 3.  
 
In the multivariate analysis adjusted for sex, HIV transmission route, and 
HBsAg status the only significant baseline factor predicting spontaneous HCV 
clearance was the IL28B genotype CC with an aOR of 5.45 (2.22-14.50), 
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p=0.0003 (data not shown). No other baseline demographic factor was 
significantly correlated with HCV clearance in the subgroup tested for IL28B 
genotype, Table 3.  
 
Compared to patients who had not been tested for IL28B the tested subgroup 
was significantly older than the non-tested group (50 versus 47 years), and 
more likely to be PWID (70% versus 56%), and less likely to be MSM (4% 
versus 12%), and also less likely to be of Asian ethnicity (3% versus 7%), 
p<0.05. There was no significant difference in sex, AIDS diagnosis, ART, 
undetectable HIV-RNA, CD4+ T-cell count or HBV status between the IL28B 
tested and non-tested individuals (data not shown).   
 
Spontaneous clearance of HCV in HIV infected individuals with a chronic 
HCV infection  
Three patients in the IL28B tested anti-HCV positive subgroup spontaneously 
cleared their chronic hepatitis C infection after introduction of ART.  
Since IL28B genotype CC was found in 122/263 tested patients, of whom 106 
were on ART, these three cases make up 3/106 (2.8%) of our patients on 
ART with genotype CC. If only IL28B genotype tested patients with genotype 
CC on ART with chronic HCV are considered in the denominator, they would 
make up 3/68 (4.4%). If the IL28B genotype distribution, the HCV chronicity 
rate and ART uptake were extrapolated to our total co-infected cohort, our 
cases would make up 3/151 (2.0%).  
In all three cases the ART caused immune reconstitution, which probably in 
turn caused the spontaneous HCV clearance. These individuals became 
HCV-RNA negative without any specific HCV therapy after previously being 
diagnosed having a chronic HCV infection with at least 2 positive HCV-RNA 
tests 6 months apart. All three had IL28B genotype CC. Their cases are 
briefly reported here. 
 
1. A 58-year-old homosexual male seroconverted simultaneously for both 
HIV and HCV genotype 4 in July 2008. He had fluctuating HCV-RNA 
levels between 847 000, 268 000 and 3 700 000 IU/ml repeatedly 
during 2008 - 2010. He had markedly elevated aminotransferases in 
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August 2009 when a liver elasticity measurement with Fibroscan 
showed a mean elasticity of 16.9 kPa indicating cirrhosis and/or active 
inflammation. ART (raltegravir, tenofovir and emtricitabine) was started 
in February 2010 when his CD4+ T-cell count was 384, but was 
interrupted after one month due to an ALT flare. At this time his 
bilirubin value was 83-193 (ULN <26), ALT 3.39-6.43 (ULN< 1.20), 
AST 6.03-22.82 (ULN< 0.76), and the HCV RNA level 225 000 IU/ml. 
The CD4+ T-cell count was 390. The flare subsided after 2 months (22 
months after the HCV diagnosis) and HCV-RNA became negative. He 
was restarted with the same ART regimen and had no flare reaction. 
Hereafter, HCV-RNA has repeatedly been tested negative during 2 
years. (Figure 1A) 
2. A 62-year-old woman with IDU 15 years earlier. HIV was diagnosed in 
1985 and HCV genotype 2b in 1993. HCV-RNA was repeatedly 
positive between 2003 and 2007 and the HCV RNA levels fluctuated 
between 2 600 000 and13 600 000 IU/ml. She had been on highly 
active ART since 1997. Her nadir CD4+ T-cell count was 240. She had 
an aminotransferase flare in December 2007. In 2008, when HCV 
therapy was planned to start HCV-RNA had spontaneously become 
negative. After this she has been continuously negative for HCV-RNA 
during 4 years. Her ART regimen at the time of HCV-RNA clearance 
was atazanavir/ritonavir, abacavir and lamuvidine and the CD4+ T-cell 
count was 438.  (Figure 1B) 
3. A 48-year-old woman with HIV diagnosed 1985 and HCV genotype 2b 
in 1997. HCV-RNA was repeatedly positive between 2001 and 2004 
with fluctuating HCV RNA between 4290 and171 000 IU/ml. She had 
been on ART since 1996 with a nadir CD4+ T-cell count of 170. At the 
time of spontaneous HCV-RNA clearance in 2005 she was on 
lopinavir/ritonavir, stavudine and tenofovir, and the CD4+ T-cell count 
was 880. After this HCV-RNA has been repeatedly negative in serum 
during 18 months[24]. (Figure 1C). 
All these three patients were repeatedly tested negative for HCV-RNA three 
times after their first negative HCV RNA test.   
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Discussion 
 
We found that three of our HIV/HCV co-infected patients spontaneously 
cleared their chronic HCV infection once they had achieved immune 
reconstitution induced by ART, all with IL28B genotype CC. Clearance of 
chronic HCV infection without specific HCV treatment is rarely seen, but 
several case-reports in HIV/HCV co-infected patients have previously been 
published [22-32]. Most of these cases, if not all, have been associated with 
immune reconstitution after initiation of ART. No information, however, has 
been provided on the IL28B genotypes in these reports. Our cases, although 
indeed rare, might support that ART should be initiated prior to HCV 
treatment, in particular in patients with the IL28B genotype CC. Another more 
direct implication is that HCV RNA testing should be done immediately before 
the initiation of HCV treatment, since a subset of HIV/HCV co-infected 
patients with IL28B CC might have cleared their chronic infection 
spontaneously.  
 
Furthermore, the IL28B genotype CC was strongly correlated with 
spontaneous clearance of acute HCV in our HIV/HCV co-infected patients. 
Thus, 36% of individuals with CC versus only 13% with non-CC 
spontaneously eradicated their HCV infection. These findings are in line with 
previous findings both in HCV mono- and HIV/HCV co-infected patients [11, 
12, 14, 15, 34-38]. Differences in baseline demographics in IL28B genotype 
tested versus untested patients were noted but these differences were 
unlikely to have had any major impact on the overall results and conclusions.  
 
The mechanism, through which the IL28B genotype and spontaneous HCV 
clearance is associated, is not well understood. The IL28B gene encodes 
interferon lambda 3, which induces antiviral activity by itself and induces 
interferon-stimulating genes (ISGs), which also have an antiviral activity. 
Favorable IL28B genotypes are associated with lower levels of pre-activated 
ISGs, but are induced more strongly after IFN-alfa treatment[15].  
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The only investigated baseline demographic factor associated with 
spontaneous HCV clearance beside the IL28B genotype in our Swedish 
HIV/HCV co-infected cohort was chronic hepatitis B. The prevalence of 
chronic HBV, however, was only 2.7%. Persons born in HBV intermediate to 
high endemic countries most likely had acquired their HBV infection vertically 
as children, before they had acquired HCV or HIV. We do not have any 
information on the order in which the patients acquired the individual viral 
infections.  
 
The association between a chronic HBV infection and a higher rate of 
spontaneous HCV clearance has been reported earlier both in HCV mono- 
and HIV/HCV co-infected patients[17-21, 39-41]. The mechanism causing this 
is not known, but viral interference has been proposed[18, 42].  
Spontaneous HCV clearance was seen in 26% females and 19% males, 
p=0.0563. Female gender has previously been associated with higher 
spontaneous clearance rate of HCV [17, 18, 21].  
 
A limitation of our study is that our definition of acute and chronic HCV does 
not rule out that there may be further cases of spontaneous clearance of 
chronic HCV among our patients. Also, a few cases of acute HCV may have 
been misclassified as chronic. HCV RNA sampling was performed in the 
clinical routine, and sometimes only one test was available.  
Another weakness in our study is the missing information of the consecutive 
order in which the HIV and HCV infections were acquired. However, we were 
able to note seroconversion for HCV in 28% in the MSM group. Regarding 
PWID, most patients in this group had probably acquired their HCV infection 
before the HIV infection as reported earlier [43]. The HIV transmission route 
indicated does not necessarily imply that this actually was the route by which 
the HCV infection was acquired. Hence, an overestimation of heterosexual 
HCV transmission was probably at hand, since heterosexual transmission of 
HCV is uncommon [44, 45].  
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In our study a total anti-HCV prevalence of 14% was found corresponding to a 
chronic HCV prevalence of 11%. Somewhat higher figures have earlier been 
reported from other European centers [8].  
 
To conclude, we found that immune reconstitution after the introduction of 
ART can induce spontaneous clearance of a chronic HCV infection in 
HIV/HCV co-infected patients with IL28B genotype CC. Furthermore, in line 
with previous reports, genotype IL28B CC was strongly correlated with the 
spontaneous clearance of acute HCV in HIV/HCV co-infected patients. These 
findings may argue for introducing ART treatment prior to commencement of 
HCV treatment in HIV/HCV co-infected patients. 
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Table	  1	  Results	  of	  HCV	  testing	  in	  HIV	  positive	  patients	  in	  Sweden	  	  
	   n	   %	  Anti-­‐HCV	  tested	   4765	  /5315	  	  	  	   90	  Anti-­‐HCV	  positive	  	   652/	  4765	   14	  HCV	  RNA	  tested	   598/	  652	   92	  HCV	  RNA	  positive	   466/593*	  	  	   79	  
	  *5	  patients	  (all	  MSM)	  were	  excluded	  due	  to	  treatment	  of	  HCV	  in	  the	  acute	  phase	  	  	   	  
	   15	  
Table 2: Demographics in 593 HIV infected anti-HCV positive patients in 
Sweden according to if they had chronic or spontaneously cleared HCV.  	  
	   Total,	  n	  (%)	   Chronic	  HCV,	  n	  (%)	   Spontaneously	  
cleared	  HCV,	  n	  (%)	  
p-­‐value	  
Patients	   593	  (100)	   466	  (79)	   127	  (21)	   NA	  
Age	  (years,	  
median,	  IQR)	  
48	  (42-­‐54)	   48	  (42-­‐54)	   49	  (41-­‐54)	   NA	  
Sex	  
Males	  
Females	  
	  410	  (69)	  183	  (31)	  
	  331	  (81)	  135	  (74)	  
	  79	  (19)	  48	  (26)	  
0.056	  	  	  
Ethnicity	  
Caucasian	  
Other	  
	  488	  (82)	  105	  (18)	  
	  385	  (79)	  81	  (77)	  
	  103(21)	  24	  (23)	  
0.12	  
Risk	  group	  
PWID	  
Heterosexual	  
MSM	  
Blood-­‐tx	  
Other/unknown	  
	  369	  (62)	  117	  (20)	  50	  (8.4)	  35	  (5.9)	  22	  (3.7)	  
	  296	  (80)	  84	  (72)	  42	  (84)	  25	  (71)	  19	  (86)	  
	  73	  (20)	  33	  (28)	  8	  (16)	  10	  (29)	  3	  (14)	  
0.17	  	  
HBV	  status	  
HBsAg	  pos	  
HBsAg	  neg	  
Not	  available	  
	  
	  16	  (2.7)	  559	  (94)	  18	  (3.0)	  
	  8	  (50)	  441(79)	  17	  (94)	  
	  8	  (50)	  118	  (21)	  1	  (6)	  	  
<0.01	  
HIV	  treatment	  
Ongoing	  
Naive	  
Pause	  
	  470	  (79)	  90	  (15)	  33	  (5.6)	  
	  366	  (78)	  77	  (86)	  23	  	  (70)	  
	  104	  (22)	  13	  (14)	  10	  (30)	  
0.10	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Table 3: Demographics and IL28B genotype in 263 IL28B genotype tested 
HIV/HCV positive patients according to if they had chronic or spontaneously 
cleared HCV infection. 	  	  
	   Total,	  n	  (%)	   Chronic	  HCV,	  n	  (%)	   Spontaneously	  
cleared	  HCV,	  n	  (%)	  
p-­‐value	  
Patients	   263	  (100)	   201	  (76)	   62	  (24)	   NA	  
Age	  (years,	  
median,	  IQR)	  
50(44-­‐54)	   50	  (44-­‐54)	   52	  (43-­‐55)	   NA	  
Sex	  
Males	  
Females	  
	  181	  (69)	  82	  (31)	  
	  144	  (80)	  57	  (70)	  
	  37	  (20)	  25	  (30)	  
0.08	  	  	  
Ethnicity	  
Caucasian	  
Other	  
	  228	  (87)	  35	  (13)	  
	  176	  (74)	  25	  (71)	  
	  52(26)	  10	  (29)	  
0.37	  
Risk	  group	  
PWID	  
Heterosexual	  
Blood-­‐tx	  
MSM	  
Other	  
	  	  183	  (70)	  52	  (20)	  12	  (4.6)	  10	  (3.8)	  	  6	  (2.3)	  
	  140	  (77)	  38	  (73)	  10(83)	  7	  (70)	  6	  (100)	  
	  43	  (23)	  14	  (27)	  2	  (17)	  3	  (30)	  0	  (0)	  
0.47	  	  	  
HBV	  status	  
HBsAg	  pos	  
HBsAg	  neg	  
	  5	  (1.9)	  258	  (98)	  
	  3	  (60)	  198	  (77)	  
	  2	  (40)	  60	  (23)	  	  
0.41	  
IL28B	  gt	  	  
CC	  
Non-­‐CC	  
	  122	  (46)	  141	  (54)	  
	  78	  (64)	  123	  (87)	  
	  44	  (36)	  18	  (13)	  
<0.001	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Fig. 1(A), (B), (C). Three HIV/HCV co-infected patients with spontaneous clearance of a 
chronic HCV infection. The arrow indicates the time of HCV-RNA disappearance. Graph 
adapted from InfCare HIV. 
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 2 
Abstract 
Background  
HCV co-infection is a leading cause of death in HIV positive patients. Despite 
a strong indication to treat HCV, treatment uptake in co-infected patients is 
generally lower than in HCV mono-infected patients.  
Our aim was to determine the HCV and HIV treatment rates and to define 
factors associated with initiation or deferral of HCV treatment in Swedish 
HIV/HCV co-infected patients. 
Methods  
All 5315 adult HIV positive patients in Sweden have been included in the 
InfCare HIV database. From this database demographic, virologic and 
treatment data from 652 HIV/HCV co-infected patients were extracted in 
September 2010.  
Factors associated with initiation of interferon-based HCV treatment were 
analysed. In a subgroup, patient- and physician-reported reasons for not 
having initiated HCV treatment were investigated. 
Results  
The anti-HCV prevalence was 14% and the chronic HCV infection rate 11%. 
In total, 25% of HIV/HCV co-infected patients had initiated HCV treatment. 
HCV genotype 2 or 3, HIV transmission route other than IDU, and on-going 
HIV treatment were factors associated with a higher HCV treatment rate. The 
main reason for not having initiated HCV treatment was IDU or alcohol abuse, 
stated by both patients and their attending physicians. 
Conclusions 
The 14% prevalence of anti-HCV noted in Swedish HIV-infected patients was 
low by international comparisons. This reflects that the MSM and 
heterosexual HIV transmission routes were dominating whereas IDU was 
relatively uncommon in our study. The 25% HCV treatment rate noted in our 
HIV/HCV co-infected patients was high and in the same magnitude of that 
published in HCV mono-infected patients in Sweden. The HIV treatment rate, 
however, was considerably higher than the HCV treatment rate. This needs to 
be improved in the future.  
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Background 
 
HIV (human immunodeficiency virus) and hepatitis C virus (HCV) co-infections 
are common due to shared routes of transmission. Hence, a total anti-HCV 
prevalence of 15-30% is noted in HIV positive persons[1]. However, the 
prevalence is dependent on the mode of HIV acquisition and varies in different 
cohorts, countries, and epidemiological settings. People who inject drugs 
(PWID) generally have the highest HCV prevalence rates[2-6]. 
Liver diseases, mainly attributable to HCV, have become a leading cause of 
death in HIV positive patients with access to antiretroviral therapy (ART) [7-
14]. End stage liver disease (ESLD) in the HIV/HCV co-infected population 
has thus increased over the last 15 years in the USA, and is presently an 
important clinical problem[15].  
To predict the future impact of ESLD in HIV/HCV co-infected patients 
knowledge of the prevalence of chronic hepatitis C in this population is 
important.  
HIV/HCV co-infected patients have faster progression of fibrosis than HCV 
mono-infected, which should translate into a strong HCV treatment indication 
[16-18]. Sustained viral response (SVR) after HCV treatment is associated 
with a lower incidence of ESLD and death [19, 20]. The number of HIV/HCV 
co-infected patients who has initiated anti-HCV treatment is generally low, and 
lower than in HCV mono-infected patients[21-28]. 
In Sweden all known HIV-infected patients have been included in a database 
(InfCare HIV) in which demographical, virological, and treatment data are 
recorded. This database was used to estimate the prevalence of HIV/HCV co-
infection in Sweden, and to examine to what extent such patients had initiated 
HCV and HIV treatment. Furthermore, factors associated with commencement 
of HCV treatment were collected. Reasons for not having initiated HCV 
treatment were investigated in a subgroup residing in Stockholm. 
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Patients and methods 
 
Inclusion of patients 
On the 28th of September 2010, 5315 adult living persons were known to be 
HIV infected in Sweden. According to the Swedish Communicable Diseases 
Act all HIV infected patients are required to keep a regular contact with their 
health care provider.  
HIV positive patients in Sweden have been prospectively included in the 
InfCare HIV research database since 2009. Retrospective data from the 
beginning of the 1990s have also been included from patients in Stockholm 
and Gothenburg.  
 
Demographical data of all living anti-HCV and anti-HIV positive adults above 
18 years (n=652) were extracted including age, sex, ethnicity, HIV 
transmission route, clinical data (prior AIDS diagnosis, CD4+ T-cell count), 
virological data (anti-HCV serology, HCV-RNA levels, HCV genotype, HIV-
RNA levels, HBV serology), HCV treatment data and antiretroviral therapy, 
(ART).   
 
Hepatitis C and B outcome definitions 
Chronic hepatitis C was defined as a positive HCV-RNA test in an anti-HCV 
positive individual. Spontaneous clearance of HCV was defined as a 
treatment naïve patient with a positive anti-HCV test but a negative HCV-RNA 
test.  
 
A patient was defined as having a chronic hepatitis B virus (HBV) infection if 
HBsAg was positive, and to have had a previous HBV infection if anti-HBc (+/- 
anti-HBs) were positive with a negative HBsAg test, and to be immune to HBV 
from vaccination when anti-HBs was positive as an isolated test.  
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Analysis of markers for HIV, HCV and HBV 
Analyses of HIV-RNA, anti-HCV antibodies, and HBV serology were 
performed at the local virological laboratories by routine techniques. HCV 
RNA was analysed in anti-HCV positive individuals with the Roche TaqMan 
Test (detection limit of 15 IU/ml). HCV genotyping was performed with a line 
probe assay or an in-house method.  
 
Hepatitis C and HIV treatment outcome 
Hepatitis C treatment had been given with interferon (IFN) or pegylated 
interferon (peg-IFN) alone or in combination with ribavirin. SVR was defined 
as an undetectable HCV RNA 6 months after HCV treatment stop. Non-
response (NR) was defined as a detectable HCV RNA test 6 months after end 
of treatment.  
Persons who had received HCV treatment for an acute hepatitis C (n=5) were 
excluded from the analyses of factors associated with treatment of chronic 
HCV.   
An undetectable HIV RNA viral load was defined as <20 HIV RNA copies/ml.  
 
Questionnaires  
A questionnaire was given to HIV/HCV co-infected patients in the Stockholm 
area who had not yet initiated HCV treatment investigating the underlying 
reasons. The attending physician was given a separate questionnaire for 
every patient he/she cared for whom had not yet initiated HCV treatment.  
 
Reasons for not having initiated HCV treatment 
Reasons for not having initiated treatment were categorized as intravenous 
drug use (IDU)/alcohol (on-going or recent abuse), patient desire not to start 
(including not motivated to initiate HCV treatment, fear of side effects, loss of 
income in case of sick leave and unstable social situation), doctors 
recommendation (including no indication due to mild fibrosis or postpone 
treatment until better HCV treatments becomes available), psychiatric 
disease, comorbidities (somatic contraindication to HCV treatment, including 
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ESLD, excluding HIV-related contraindications), HIV/AIDS (uncontrolled HIV 
infection, on-going opportunistic infection), don´t know or other.  
The questionnaires from every patient-doctor pair were assessed for 
agreement or discrepancies concerning the main reason stated for not having 
initiated HCV treatment.  
Patients were also asked if any intravenous drug had been used during the 
previous 6 months, and to state their current alcohol consumption.  
 
Statistics 
Differences between groups were compared with chi-square test for 
categorical variables and the Wilcoxon Rank Sum test for continuous 
variables.  
When analysing the importance of baseline demographic factors for having 
initiated HCV treatment or not we included age, sex, ethnicity, born in Sweden 
or not, HIV transmission route, prior AIDS diagnosis, CD4+ T-cell count, 
present ART, plasma HIV-RNA level, HBsAg status, HCV genotype and 
department (university clinic or not) in the univariate model. Factors with a p-
value <0.10 were included in a multivariate model. Logistic regression was 
used to identify variables associated with having started HCV treatment. The 
results are presented as odds ratio (OR) and adjusted OR (aOR) with 95% 
confidence intervals (CI).   
A p-value of < 0.05 was considered statistically significant.     
All data were analysed using JMP software version 9.0.0.  
 
 
Ethics 
The study was performed in accordance with the Declaration of Helsinki and 
was approved by the Regional Ethics committee (Dnr 2010/1782-31 and 
2011/514-31/1).  
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Results   
 
Prevalence of anti-HCV 
In total, 5315 persons >/= 18 years were HIV positive in Sweden in 
September 2010. The transmission route for HIV was heterosexual in 50%, 
men who have sex with men (MSM) in 32%, and IDU in 8%. Transmission via 
blood transfusion, mother to child transmission, and via other or unknown 
routes accounted for less than 10% (data not shown).   
 
In 4765 (90%) persons anti-HCV test results were available whereof 652 
(14%) were anti-HCV positive (Figure 1).  
550 patients (10%) lacked an anti-HCV test result. In this group 46% were 
females vs. 36% in the anti-HCV tested group. The corresponding figures for 
PWID were 2.2% versus 8.6%, for MSM 28% versus 34%, and for those with 
a prior AIDS diagnosis 9.6% versus 16%, (p<0.05 for all comparisons). There 
was no significant difference in age or ethnicity between anti-HCV tested and 
non-tested (data not shown).   
 
The prevalence of anti-HCV varied markedly according to the HIV 
transmission route. Hence, 98% of PWID, 41% of persons who acquired HIV 
via blood transfusion, 5.5 % of those heterosexually HIV infected, and 3.7% of 
MSM were anti-HCV positive (p<0.01) (Figure 2). 
Among persons who had acquired HIV in Sweden the anti-HCV prevalence 
was 26% versus 6.2% in persons who were infected abroad, p<0.0001. The 
anti-HCV prevalence was higher in males than in females, 15% versus 12%, 
p=0.01 (data not shown).     
 
Chronic HCV in HIV infected individuals 
HCV RNA testing had been performed in 598/652 (92%) patients of whom 
79% tested positive (Figure 1). These were defined as having a chronic 
hepatitis C infection, corresponding to a chronic HCV prevalence of 11%. 
Spontaneous clearance of HCV was noted in 127/593 (21%). The IL28B 
 8 
genotype CC and HBsAg positivity were the only factors significantly 
associated with spontaneous clearance of HCV [29].    
 
Patients lacking a HCV RNA test (n=54) were more likely to be ART naive 
than those tested, 30% versus 15%, p<0.01. No significant difference 
regarding gender, age, HIV transmission route or ethnicity was noted between 
individuals tested or not tested (data not shown).    
 
In total, 471 individuals tested HCV RNA positive. Five MSM patients had 
received HCV treatment for an acute HCV infection, of whom four had 
achieved SVR. These persons were therefore excluded from further analysis. 
Demographics in the 466 HIV/HCV co-infected patients in Sweden are 
depicted in Table 1.  
In total, 366/466 (79%) patients had on-going ART of whom 285 (76%) had 
undetectable HIV RNA levels (<20 copies/ml)(Table 1).  
 
The HCV genotype was available in 354 (76%) of the HIV/HCV co-infected 
individuals. HCV genotype 1, 2, 3a and 4-6 was seen in 52%, 12 %, 31%, and 
6.2% respectively (Figure 3). Genotype 1a constituted 75% of all genotype 1 
cases.  
Eight persons (1.7%) also had a chronic hepatitis B virus infection, 68% had 
had a past HBV infection and 6.0% were isolated anti-HBs positive (data not 
shown). 
 
In total, 118/466 (25%) patients had received HCV treatment.  
Among those who had completed their treatment 57/103 (55%) had achieved 
SVR. Fifteen patients had on-going HCV treatment or had not completed 
follow-up. The SVR rate varied according to HCV genotype and was 31% in 
genotype 1, 87% in genotype 2, and 70% in genotype 3. 
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Factors associated with initiation of HCV treatment  
Demographical data in the 466 patients with chronic HCV infection are 
depicted in Table 1 according to having initiated HCV treatment or not. The 
univariate and multivariate odds ratios (ORs) for having initiated HCV 
treatment are given in Table 2.  
 
The HCV treatment rate varied significantly according to the HIV transmission 
route. Hence, it was 20% in PWID, 29% in heterosexuals, 38% in MSM and 
44% in persons infected via blood transfusion (p<0.01)(Table 1 and Figure 3).   
MSM and persons who had acquired HIV infection via blood transfusion had 
increased odds of having initiated HCV treatment compared to PWID: aOR 
2.60 (95% CI, 1.13-5.92), p= 0.02 and aOR 3.24 (95% CI 1.23-8.59), p=0.02, 
respectively (Table 2).  
  
For comparison, the HIV treatment rate in HIV/HCV co-infected patients 
according to HIV transmission route is depicted in Figure 3. There was no 
significant difference in HIV treatment rate according to transmission route. A 
trend, however, was noted for persons who acquired their HIV infection via 
blood transfusion to have a higher HIV treatment rate than PWID, 23/25 
(92%) vs. 227/296 (77%), p=0.0501 (data not shown).   
 
Patients with HCV genotype 2 or 3 had increased odds of having initiated 
HCV treatment when compared with patients with HCV genotype 1, 4, 5 or 6: 
aOR 2.19 (95% CI. 1.33-3.65), p=0.0021 (Table 2).  
 
Patients with on-going ART had increased odds of having initiated HCV 
treatment compared with ART naive patients: aOR 3.40 (95% CI 1.42-9.56), 
p=0.0045 (Table 2). Patients with undetectable HIV-RNA had a higher HCV 
treatment rate than patients with detectable HIV-RNA during on-going ART in 
the univariate analysis. This difference, however, was not significant in the 
multivariate analysis (Table 2). 
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There were no significant difference in HCV treatment rate according to 
gender, age, ethnicity (Caucasian vs. non-Caucasian), country of birth 
(Sweden or not), prior AIDS diagnosis or not, CD4+ T-cell count or having a 
chronic hepatitis B or not (Table 1, data not shown).  
 
Reasons for not having initiated HCV treatment  
 
The HIV/HCV co-infected cohort in Stockholm  
In total 322 patients in Stockholm were HIV/HCV co-infected. The Stockholm 
cohort constituted 322/466 (69%) of the total HIV/HCV co-infected cohort in 
Sweden. Of these persons, 82 (25%) had received HCV treatment whereas 
240 had not.   
The HIV/HCV co-infected cohort in Stockholm included more Caucasians 
(88% versus 71%), PWID (67% versus 55%), and MSMs (11% versus 5%), 
than the rest of the Swedish cohort (p<0.05). Other demographics and 
baseline characteristics were similar.  
 
Questionnaires in patients and attending physicians  
Among the 240 patients eligible for inclusion, four patients had received HCV 
treatment, 12 (5%) had died and 18 moved from the catchment area. Hence 
206 could be asked to participate whereof 114 (55%) answered the 
questionnaire. Very few patients (n=3) declined participation, however, some 
did not attend the HIV outpatient department regularly within the study period.   
The responders were more often born in Sweden (83% vs. 67%), and more 
likely to have on-going ART (81 vs. 63%) than the non-responders (p<0.05). 
Among responders 80% were PWID, vs. 67% of non-responders. There was 
no significant difference regarding age, gender, CD4+ T-cell count, AIDS 
diagnosis, or HCV genotype between responding and non-responding co-
infected patients.   
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Among the 16 attending physicians who cared for the HIV/HCV co-infected 
patients (3-26 co-infected patients/physician) the response rate was 210/240 
(88%).      
 
Patient questionnaire results 
The results of the questionnaires answered by HIV/HCV co-infected patients 
are depicted in Figure 4a. The main reason for not having initiated HCV 
treatment was on-going/recent IDU or alcohol abuse (stated by 26%), followed 
by patient desire/social situation (22%) and doctor´s recommendation (22%). 
Among patients 68/114 (60%) stated that they had been offered HCV 
treatment by their caregiver. Today, 68/114 (60%) would accept such an offer. 
52/114 (46%) had injected drugs intravenously during the last 6 months.  
 
Physician questionnaire results 
Answers given by the attending physicians are depicted in Figure 4b. 
Reasons for not having initiated HCV treatment as stated by the attending 
physician were on-going/recent IDU or alcohol abuse in 53 % (9% had 
concomitant psychiatric disease), patient´s desire in 16%, doctor´s 
recommendation in 15%, psychiatric disease in 9%, and somatic co-
morbidities in 7%. In one patient (0.5%) HIV/AIDS was the main reason for 
not having initiated HCV treatment.  
In 22/210 (10%) of all patients, the attending physicians deemed it possible to 
start interferon including HCV treatment soon. In 71/210 (34%) HCV treatment 
including interferon was considered to be intolerable.   
 
The agreement between patient and physician stated main reason for each 
patient-doctor pair was 59% (data not shown).    
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Discussion 
 
Prevalence of anti-HCV  
Among Swedish HIV infected patients, a total anti-HCV prevalence of 14% 
was found. Higher figures have earlier been reported from a European study 
[3]. The MSM and heterosexual transmission routes were dominating whereas 
PWID was relatively uncommon in our patients but not in the European 
cohort. This might explain the lower prevalence found in our study.  
The nearly universal (90%) anti-HCV testing in the Swedish cohort minimizes 
the risk of selection bias. However, since female sex and HIV transmission 
routes other than IDU and MSM were overrepresented among our patients 
untested for HCV markers, the 14% prevalence found in our study might be 
an overestimation.  
 
HCV prevalence according to HIV transmission route 
The varying anti-HCV prevalence found according to the HIV transmission 
route is expected [1-6]. Thus, a very high anti-HCV prevalence was found 
among our PWIDs (98%). HIV is still a rare disease among PWIDs in Sweden, 
with an estimated prevalence of <5% [30]. HCV on the other hand is very 
common [30]. Hence, HCV is probably acquired earlier than HIV in most HIV 
infected PWID. A needle exchange program is available in a few cities in 
Sweden and has only very recently started in Stockholm. Subsequently, this 
program has not yet had any major impact on the HCV prevalence.   
 
In the MSM group an anti-HCV prevalence of only 3.7% was found. However, 
not all clinics had yet implemented anti-HCV testing on a yearly basis in MSM 
persons. Hence, this figure might be an underestimation. Several cases of 
acute HCV infection were noted in our MSM cohort as reported elsewhere[31-
33].  
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Chronic HCV in HIV infected persons 
A chronic HCV prevalence of 11% was noted in the Swedish HIV infected 
cohort. The HCV genotype distribution was similar to that found in HCV mono-
infected patients in Sweden [34], and in HIV/HCV co-infected patients 
reported in the Euro-SIDA cohort [35, 36].  
 
HCV treatment uptake 
The cumulative HCV treatment uptake of 25% noted in our study in 2010 is 
similar to that noted in the Euro-SIDA cohort in the same year [36]. HCV 
treatment uptakes between 2% and 60% has been reported in HIV/HCV co-
infected patients, partly depending on the selection of patients included [21-
28].  
In 2005 the national cumulative HCV treatment uptake in Sweden was 12% 
[27]. This estimate was based on sales of peg-IFN and an estimated national 
HCV prevalence of 0.5%.  
In 2006 a 14% HCV treatment uptake was reported in Sweden, based on 
1000 peg-IFN prescriptions per year between 2001 and 2006 and 43 000 
notified HCV infected individuals [37].  
The 25% HCV treatment uptake in our study is thus comparatively high 
indicating a treatment uptake in HIV/HCV co-infected patients in the same 
order as that published in HCV mono-infected patients in Sweden.  
 
Factors associated with initiation of HCV treatment  
A higher HCV treatment rate was seen in HCV genotype 2 or 3 infected 
patients, in patients with HIV transmission routes other than IDU, and in 
patients with on-going ART.  
Being infected with HCV genotype 2 or 3 was independently associated with 
initiation of HCV treatment, probably because of higher SVR rates and the 
short treatment duration. The lower HCV treatment uptake among PWIDs 
compared to patients with other HIV transmission routes was most likely due 
to many factors (including on-going IDU) rending the provider less inclined to 
offer treatment for this group. Indeed, in HIV/HCV co-infected patients in 
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Stockholm, the main reason for not having initiated HCV treatment as stated 
by both patients and their physician, was on-going IDU/alcohol abuse. 
Somatic comorbidities and HIV/AIDS were uncommon.   
Patients with on-going ART also had a higher HCV treatment uptake. This 
could reflect their assumed better adherence to any treatment.  
The HIV treatment rate and rate of undetectable HIV viral load, indicate that 
many patients who had not initiated HCV treatment were adherent to their HIV 
treatment. A discrepancy between treatment initiation for HIV and HCV was 
obvious, since many more patients had initiated ART than HCV treatment. 
Certainly, ART is more urgent and all patients will need ART eventually 
whereas HCV treatment might be postponed if the rate of fibrosis progression 
is slow.  
However, when interferon-free DAA combinations soon will become available, 
HCV treatment should expand to include more HIV/HCV co-infected patients 
in order to prevent morbidity and mortality from HCV in this population.  
 
Conclusion 
We found an anti-HCV prevalence of 14% and a chronic HCV infection rate of 
11% in the total HIV infected cohort in Sweden. Of these, 25% had received 
HCV treatment, a figure in the same range as in published data on HCV 
mono-infected patients. A higher HCV treatment rate was seen in HCV 
genotype 2 or 3 infected patients, persons with HIV transmission route other 
than IDU, and in patients with on-going ART. The main reason for not having 
initiated HCV treatment among our HIV/HCV co-infected patients in 
Stockholm was IDU or alcohol abuse. 
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Figure 1 HIV-infected patients with chronic hepatitis C in Sweden 2010  
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Figure 2: The anti-HCV prevalence in percentage according to HIV 
transmission group in HIV infected Swedish patients 
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Table 1: Baseline and clinical characteristics in HIV/HCV co-infected patients in 
Sweden according to having initiated HCV treatment or not   
 
 Total, n(%) HCV treated, n(%) Not HCV treated, n(%) p-value 
Patients 466 (100) 118 (25) 348 (74)  
Age (median, IQR) 48 (42-54) 49 (42-55) 48 (42-53) 0.44 
Gender 
Males 
Females 
 
331 (71) 
135(29) 
 
82 (25) 
36 (27) 
 
249 (75) 
99 (73) 
0.67 
Ethnicity 
Caucasian 
Other 
Missing 
 
385 (83)  
49 (11)  
33 (7.1) 
 
96(25) 
20 (41) 
2 (6.1) 
 
289 (75) 
29 (59) 
31 (94) 
0.67 
Transmission route 
IDU 
Heterosexual 
MSM 
Blood tx 
Other 
 
296(64) 
84 (18)  
42  (9) 
25  (5.4) 
19  (4.1) 
 
58 (20) 
24 (29) 
16 (38) 
11 (44) 
9 (47) 
 
238 (80) 
60 (71) 
26 (62) 
14 (56) 
10 (53) 
<0.01 
HCV genotype 
1 
2 
3 
4-6 
missing 
 
183 (39) 
41 (8.8) 
108 (23) 
22  (4.7) 
112 (24) 
 
45(25) 
15 (37) 
39 (36) 
4   (18) 
15 (13) 
 
138 (75) 
26  (63) 
69   (64) 
18   (82) 
97   (87) 
0.01 
HIV treatment 
Ongoing 
Naive 
Pause 
 
366 (79) 
77  (17) 
23 (4.9) 
 
104 (28) 
9   (12) 
5  (22) 
 
262 (72) 
68  (88) 
18  (88) 
<0.01  
HIV RNA undet 
Yes 
No 
Not on HIV tx 
 
285 (61) 
91   (20) 
90  (19) 
 
89 (31) 
16  (18) 
13   (14) 
 
196 (69) 
75  (82) 
77   (86) 
<0.01 
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Table 2: Variables associated with having started HCV treatment in HIV/HCV co-
infected patients in Sweden, n=466  
Data are presented as Odds Ratio (OR) and adjusted OR (aOR) with 95% confidence interval 
(CI)  
 
 Univariate  Multivariate  
Variable (n) OR (95% CI) p-value aOR (95% CI) p-value 
Transmission route  
IDU (296) 
Heterosexual (84) 
MSM (42) 
Blood tx (25) 
Other (19) 
1 (reference) 
1.64 (0.93-2.83) 
2.53 (1.25-4.98) 
3.22 (1.37-7.46) 
5.47 (1.83-17.20) 
 
 
0.085 (ns) 
0.010 
0.0084 
0.0027 
 
1 (reference) 
1.33 (0.69-2.48) 
2.60 (1.13-5.92) 
3.24 (1.23-8.59)  
6.59 (1.90-25.07) 
 
 
0.38 (ns) 
0.025  
0.018 
0.0033 
HCV genotype 
1,4-6 (205) 
2,3 (149) 
 
1 (reference) 
1.81 (1.14-2.88) 
 
 
0.019 
 
1 (reference) 
2.19 (1.33-3.65) 
 
 
0.0021 
HIV treatment 
Naive (77) 
Ongoing (366) 
 
1 (reference) 
3.00 (1.51-6.65) 
 
 
0.0011 
 
1 (reference) 
3.40 (1.42-9.56) 
 
 
0.0045 
HIV RNA undet 
No (91) 
Yes (285) 
 
1 (reference) 
2.13 (1.20-3.97) 
 
 
0.0090 
 
1 (reference) 
1.84 (0.93-3.83) 
 
 
0.078 (ns) 
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Figure 3: HIV and HCV treatment uptake in percentage in HIV/HCV 
co-infected patients (n=466) according to HIV transmission route 
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Figure 4: Reasons stated for not having initiated HCV treatment in  
HIV/HCV co-infected patients in Stockholm  
a. In patients  (n=114) 
b. In physicians (n=210) 
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